AU2013203696A1 - Recombinant Viral Vectors and Uses Therefor - Google Patents
Recombinant Viral Vectors and Uses Therefor Download PDFInfo
- Publication number
- AU2013203696A1 AU2013203696A1 AU2013203696A AU2013203696A AU2013203696A1 AU 2013203696 A1 AU2013203696 A1 AU 2013203696A1 AU 2013203696 A AU2013203696 A AU 2013203696A AU 2013203696 A AU2013203696 A AU 2013203696A AU 2013203696 A1 AU2013203696 A1 AU 2013203696A1
- Authority
- AU
- Australia
- Prior art keywords
- nucleotide sequence
- recombinant
- hdv
- genome
- heterologous nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013603 viral vector Substances 0.000 title abstract description 7
- 208000037262 Hepatitis delta Diseases 0.000 claims abstract description 256
- 208000029570 hepatitis D virus infection Diseases 0.000 claims abstract description 237
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 41
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 24
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 24
- 208000005331 Hepatitis D Diseases 0.000 claims abstract description 22
- 239000013598 vector Substances 0.000 claims abstract description 10
- 208000006454 hepatitis Diseases 0.000 claims abstract description 9
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 8
- 241000724709 Hepatitis delta virus Species 0.000 claims description 303
- 239000002773 nucleotide Substances 0.000 claims description 207
- 125000003729 nucleotide group Chemical group 0.000 claims description 206
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 171
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 157
- 229920001184 polypeptide Polymers 0.000 claims description 154
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 134
- 108091007433 antigens Proteins 0.000 claims description 129
- 239000000427 antigen Substances 0.000 claims description 128
- 102000036639 antigens Human genes 0.000 claims description 127
- 108091026890 Coding region Proteins 0.000 claims description 101
- 238000000034 method Methods 0.000 claims description 93
- 241000700605 Viruses Species 0.000 claims description 83
- 210000004027 cell Anatomy 0.000 claims description 83
- 108700026244 Open Reading Frames Proteins 0.000 claims description 77
- 230000000295 complement effect Effects 0.000 claims description 57
- 230000028993 immune response Effects 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 42
- 238000011144 upstream manufacturing Methods 0.000 claims description 42
- 208000015181 infectious disease Diseases 0.000 claims description 36
- 102000004127 Cytokines Human genes 0.000 claims description 30
- 108090000695 Cytokines Proteins 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 30
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 29
- 230000008488 polyadenylation Effects 0.000 claims description 28
- 102000014150 Interferons Human genes 0.000 claims description 26
- 108010050904 Interferons Proteins 0.000 claims description 26
- 230000001225 therapeutic effect Effects 0.000 claims description 26
- 230000006337 proteolytic cleavage Effects 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 244000052769 pathogen Species 0.000 claims description 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 19
- 238000000137 annealing Methods 0.000 claims description 19
- 229940079322 interferon Drugs 0.000 claims description 19
- 108090000994 Catalytic RNA Proteins 0.000 claims description 18
- 102000053642 Catalytic RNA Human genes 0.000 claims description 18
- 108091092562 ribozyme Proteins 0.000 claims description 18
- 230000001717 pathogenic effect Effects 0.000 claims description 17
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 14
- 239000002243 precursor Substances 0.000 claims description 14
- 230000002519 immonomodulatory effect Effects 0.000 claims description 10
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 claims description 9
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 210000003494 hepatocyte Anatomy 0.000 claims description 6
- 241001533413 Deltavirus Species 0.000 claims description 5
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 4
- 230000000961 alloantigen Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 210000000805 cytoplasm Anatomy 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229960001438 immunostimulant agent Drugs 0.000 claims description 3
- 239000003022 immunostimulating agent Substances 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000005945 translocation Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 15
- 230000003612 virological effect Effects 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000009385 viral infection Effects 0.000 abstract description 5
- 230000010354 integration Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 136
- 102000004169 proteins and genes Human genes 0.000 description 66
- 238000003780 insertion Methods 0.000 description 23
- 230000037431 insertion Effects 0.000 description 21
- 108020004999 messenger RNA Proteins 0.000 description 20
- 150000001413 amino acids Chemical group 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000014616 translation Effects 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 238000013519 translation Methods 0.000 description 16
- 241000700721 Hepatitis B virus Species 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000000087 stabilizing effect Effects 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 241000710188 Encephalomyocarditis virus Species 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 241000711549 Hepacivirus C Species 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 231100000611 venom Toxicity 0.000 description 8
- 230000001018 virulence Effects 0.000 description 8
- 108090000467 Interferon-beta Proteins 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 229940047124 interferons Drugs 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 244000000010 microbial pathogen Species 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 239000002435 venom Substances 0.000 description 7
- 210000001048 venom Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 239000013566 allergen Substances 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 102000003996 Interferon-beta Human genes 0.000 description 4
- -1 Leu Chemical compound 0.000 description 4
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 4
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 4
- 102000009572 RNA Polymerase II Human genes 0.000 description 4
- 108010009460 RNA Polymerase II Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229960001388 interferon-beta Drugs 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102100026720 Interferon beta Human genes 0.000 description 3
- 102000000704 Interleukin-7 Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 102000017143 RNA Polymerase I Human genes 0.000 description 3
- 108010013845 RNA Polymerase I Proteins 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 241000219496 Alnus Species 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- 244000281762 Chenopodium ambrosioides Species 0.000 description 2
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 2
- 235000005490 Chenopodium botrys Nutrition 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 108091028075 Circular RNA Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 240000005109 Cryptomeria japonica Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000209210 Dactylis Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 101150103227 IFN gene Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102100022469 Interferon kappa Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000721662 Juniperus Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 102100023123 Mucin-16 Human genes 0.000 description 2
- 102100034263 Mucin-2 Human genes 0.000 description 2
- 108010008705 Mucin-2 Proteins 0.000 description 2
- 241000795633 Olea <sea slug> Species 0.000 description 2
- 241001504519 Papio ursinus Species 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000282695 Saimiri Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- 206010042566 Superinfection Diseases 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 241000218636 Thuja Species 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 108010080375 interferon kappa Proteins 0.000 description 2
- 108700027921 interferon tau Proteins 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 241000209136 Agropyron Species 0.000 description 1
- 241000743339 Agrostis Species 0.000 description 1
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 241000223602 Alternaria alternata Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000743857 Anthoxanthum Species 0.000 description 1
- 240000004178 Anthoxanthum odoratum Species 0.000 description 1
- 235000014251 Anthoxanthum odoratum Nutrition 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000508787 Arrhenatherum Species 0.000 description 1
- 241000508786 Arrhenatherum elatius Species 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
- HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 1
- 235000005781 Avena Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241000219429 Betula Species 0.000 description 1
- 235000003932 Betula Nutrition 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000238658 Blattella Species 0.000 description 1
- 241000238657 Blattella germanica Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000209200 Bromus Species 0.000 description 1
- 241000743756 Bromus inermis Species 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 101150042405 CCN1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000288951 Callithrix <genus> Species 0.000 description 1
- 241000589994 Campylobacter sp. Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108091036055 CccDNA Proteins 0.000 description 1
- 241000723437 Chamaecyparis Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000010471 Chronic Hepatitis D Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000238586 Cirripedia Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000239250 Copepoda Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000723198 Cupressus Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- ZGERHCJBLPQPGV-ACZMJKKPSA-N Cys-Ser-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N ZGERHCJBLPQPGV-ACZMJKKPSA-N 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 241000238713 Dermatophagoides farinae Species 0.000 description 1
- 101000827699 Drosophila melanogaster Fibroblast growth factor receptor homolog 2 Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000508725 Elymus repens Species 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241001523858 Felipes Species 0.000 description 1
- 241000234642 Festuca Species 0.000 description 1
- 241000234645 Festuca pratensis Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZZJVYSAQQMDIRD-UWVGGRQHSA-N Gly-Pro-His Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O ZZJVYSAQQMDIRD-UWVGGRQHSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000657230 Hepatitis delta virus dFr2012 Species 0.000 description 1
- 241000657033 Hepatitis delta virus dFr2042 Species 0.000 description 1
- 241000657032 Hepatitis delta virus dFr2043 Species 0.000 description 1
- 241000657247 Hepatitis delta virus dFr2045 Species 0.000 description 1
- 241000656376 Hepatitis delta virus dFr2046 Species 0.000 description 1
- 241000657211 Hepatitis delta virus dFr2067 Species 0.000 description 1
- 241000656372 Hepatitis delta virus dFr2119 Species 0.000 description 1
- 241000657214 Hepatitis delta virus dFr2137 Species 0.000 description 1
- 241000657213 Hepatitis delta virus dFr2172 Species 0.000 description 1
- 241000657202 Hepatitis delta virus dFr2189 Species 0.000 description 1
- 241000657201 Hepatitis delta virus dFr2201 Species 0.000 description 1
- 241000657034 Hepatitis delta virus dFr2210 Species 0.000 description 1
- 241000657233 Hepatitis delta virus dFr2236 Species 0.000 description 1
- 241000656373 Hepatitis delta virus dFr2239b Species 0.000 description 1
- 241000657231 Hepatitis delta virus dFr2244 Species 0.000 description 1
- 241000657235 Hepatitis delta virus dFr2258 Species 0.000 description 1
- 241000657234 Hepatitis delta virus dFr2264 Species 0.000 description 1
- 241000656375 Hepatitis delta virus dFr2284 Species 0.000 description 1
- 241000657237 Hepatitis delta virus dFr2380 Species 0.000 description 1
- 241000656377 Hepatitis delta virus dFr2395 Species 0.000 description 1
- 241000657236 Hepatitis delta virus dFr2404 Species 0.000 description 1
- 241000657239 Hepatitis delta virus dFr2406 Species 0.000 description 1
- 241000657238 Hepatitis delta virus dFr2411 Species 0.000 description 1
- 241000656370 Hepatitis delta virus dFr2544 Species 0.000 description 1
- 241000656327 Hepatitis delta virus dFr508 Species 0.000 description 1
- 241000656188 Hepatitis delta virus dTk2 Species 0.000 description 1
- 241000656205 Hepatitis delta virus dTk21 Species 0.000 description 1
- 241000656166 Hepatitis delta virus dTk27 Species 0.000 description 1
- 241000656168 Hepatitis delta virus dTk28 Species 0.000 description 1
- 241000656169 Hepatitis delta virus dTk3 Species 0.000 description 1
- 241000656170 Hepatitis delta virus dTk34 Species 0.000 description 1
- 241000656378 Hepatitis delta virus dTk35 Species 0.000 description 1
- 241000656172 Hepatitis delta virus dTk38 Species 0.000 description 1
- 241000656362 Hepatitis delta virus dTk4 Species 0.000 description 1
- 241000656171 Hepatitis delta virus dTk5 Species 0.000 description 1
- 241000656178 Hepatitis delta virus dTk6 Species 0.000 description 1
- 241000656167 Hepatitis delta virus dTk7 Species 0.000 description 1
- 241000656174 Hepatitis delta virus dTk8 Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000226709 Hesperocyparis arizonica Species 0.000 description 1
- 241001290232 Hesperocyparis macrocarpa Species 0.000 description 1
- RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241000744855 Holcus Species 0.000 description 1
- 240000003857 Holcus lanatus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000616456 Homo sapiens MEF2-activating motif and SAP domain-containing transcriptional regulator Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- 241000721668 Juniperus ashei Species 0.000 description 1
- 241000592238 Juniperus communis Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 244000100545 Lolium multiflorum Species 0.000 description 1
- 240000004296 Lolium perenne Species 0.000 description 1
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
- 102100021795 MEF2-activating motif and SAP domain-containing transcriptional regulator Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000721578 Melopsittacus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000710185 Mengo virus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000238590 Ostracoda Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001465379 Parietaria judaica Species 0.000 description 1
- 241000721464 Parietaria officinalis Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001330453 Paspalum Species 0.000 description 1
- 241001330451 Paspalum notatum Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000238661 Periplaneta Species 0.000 description 1
- 241000238675 Periplaneta americana Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000745991 Phalaris Species 0.000 description 1
- 244000081757 Phalaris arundinacea Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- PYOHODCEOHCZBM-RYUDHWBXSA-N Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 PYOHODCEOHCZBM-RYUDHWBXSA-N 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 241000746981 Phleum Species 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 244000239204 Plantago lanceolata Species 0.000 description 1
- 235000010503 Plantago lanceolata Nutrition 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000209048 Poa Species 0.000 description 1
- 241000136254 Poa compressa Species 0.000 description 1
- 244000133771 Poa nemoralis Species 0.000 description 1
- 241000209049 Poa pratensis Species 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 244000274906 Quercus alba Species 0.000 description 1
- 235000009137 Quercus alba Nutrition 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 244000004774 Sabina virginiana Species 0.000 description 1
- 235000008691 Sabina virginiana Nutrition 0.000 description 1
- 241000288959 Saguinus Species 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 244000082988 Secale cereale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101710149279 Small delta antigen Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 240000006694 Stellaria media Species 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GQPQJNMVELPZNQ-GBALPHGKSA-N Thr-Ser-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O GQPQJNMVELPZNQ-GBALPHGKSA-N 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
- FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108010045648 interferon omega 1 Proteins 0.000 description 1
- 108010018844 interferon type III Proteins 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000003157 protein complementation Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000724775 unclassified viruses Species 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Chemical class 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
- C12N2760/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
- C12N2760/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
- C12N2760/10141—Use of virus, viral particle or viral elements as a vector
- C12N2760/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
- C12N2760/10151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/52—Vector systems having a special element relevant for transcription encoding ribozyme for self-inactivation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Abstract
This invention discloses recombinant hepatitis delta viral (HDV) vectors that are useful inter alia in the treatment or prevention of hepatitis virus infections. The viral vectors are predicated on the stable integration of heterologous nucleic acid 5 sequences into a HDV genome, which confer a substantially rod-like secondary structure on the resulting recombinant HDV genome.
Description
TITLE OF THE INVENTION "RECOMBINANT VIRAL VECTORS AND USES THEREFOR" [0001] This application claims priority to Australian Provisional Application No. 2012902684 entitled "Recombinant Viral Vectors and Uses Therefor" filed 25 June 5 2012, the contents of which are incorporated herein by reference in their entirety. FIELD OF THE INVENTION [0002] This invention relates generally to recombinant hepatitis delta viral vectors that can be used, for example, in the treatment or prevention of hepatitis virus infections. The invention further relates to compositions and methods that employ these 10 vectors. BACKGROUND OF THE INVENTION [0003] Hepatitis delta virus (HDV) is a subviral satellite as it can only propagate in the presence of hepatitis B virus (HBV). Indeed, HDV can only productively infect individuals who have HBV, and currently 15 million are co-infected 15 worldwide. Of significance, superinfection of HBV carriers with HDV causes severe liver disease and results in a high rate of chronicity. [0004] HDV is a small, spherical virus with a 36 nm diameter. It has an outer coat containing three hepatitis B virus (HBV) envelope proteins (designated large, medium, and small hepatitis B surface antigens), and host lipids surrounding an inner 20 nucleocapsid. The nucleocapsid contains a negative sense, single-stranded, closed circular RNA of approximately 1700 nucleotides and about 200 molecules of hepatitis D antigen (HDAg) for each genome. The central region of HDAg has been shown to bind RNA. [0005] The HDV circular genome is unique to animal viruses because it is the 25 smallest known viral genome that infects mammals and has a high G/C nucleotide content (about 60%). Additionally, its nucleotide sequence is about 70% self complementary, allowing the HDV genome to form a partially double-stranded RNA structure that is described as "rod-like." [0006] During replication, three forms of RNA are made using host cell RNA 30 polymerases; circular genomic RNA, circular complementary antigenomic RNA, and a linear polyadenylated antigenomic RNA, which is the mRNA containing the open - 1 reading frame for the HDAg. Initial studies implicated RNA polymerase II in HDV replication; however, one study has shown that RNA polymerases I and III also interact with HDV RNA, suggesting a more complex reliance on several host polymerases (Greco-Stewart et al., 2009.Virology 386: 12-15). Evidence suggests that synthesis of 5 the different RNA species occurs in different subcellular locations, mediated by distinct cellular polymerases: synthesis of antigenomic RNA occurs in the nucleolus mediated by RNA polymerase I, whereas synthesis of genomic RNA takes place more diffusely in the nucleoplasm by RNA polymerase II (Li et al., 2006. J Virol 80: 6478-6486). Notably, the RNA polymerases treat the HDV RNA genome as double-stranded DNA 10 due to the folded rod-like structure it is in and possibly due to the action of the HDAg. A schematic representation of wild-type HDV genomic RNA, antigenomic RNA and mRNA is shown in Figure 1. [0007] Replication of the circular HDV RNA template occurs via a rolling circle mechanism that is unique to animal viruses but analogous to that of plant viroids. 15 HDV RNA is synthesized first as linear RNA that contains many copies of the genome. The genomic and antigenomic RNA contain a sequence of about 85 nucleotides that acts as a ribozyme, which self-cleaves the linear RNA into monomers. These monomers are then ligated to form circular RNA. [0008] HDV uses ADARI editing of the viral antigenome RNA to switch 20 from viral RNA replication to packaging. At early times in the replication cycle, the virus produces a short form of HDAg, termed HDAg-S, which is required for RNA synthesis. At later times, as result of editing at the amber/W site, the virus produces a long form of HDAg, termed HDAg-L, which is required for packaging, but inhibits further RNA synthesis as levels increase. 25 [0009] HDV superinfection in HBV-infected individuals often results in chronic HDV, which further increases the mortality rate associated with chronic hepatitis B. Unfortunately, however, present therapies often fail to resolve chronic hepatitis, are expensive, and have serious side-effects. [0010] Accordingly, there is an urgent need to develop effective means for 30 treating or preventing hepatitis infections, including chronic hepatitis B/D infections. -2- SUMMARY OF THE INVENTION [0011] The present inventors have developed a novel strategy for stably inserting heterologous nucleotide sequences into the HDV genome. In particular, they have discovered that it is possible to stably insert an heterologous nucleotide sequence 5 into a site of a HDV genome provided that a substantially complementary heterologous nucleotide sequence is inserted into another site of the HDV genome whereby the heterologous nucleotide sequences are in juxtaposition to permit annealing to each other and to thereby maintain the rod-like secondary structure of the HDV genome and confer stability thereto. 10 [0012] Accordingly, in one aspect, the present invention provides recombinant single-stranded, circular hepatitis delta virus (HDV) RNA genomes. These genomes generally comprise or consist essentially of in operable connection: a promoter; an open reading frame (ORF) for a hepatitis delta antigen (HDAg); a polyadenylation signal; and a HDV ribozyme, wherein the genomes comprise 15 substantially complementary portions conferring a rod-like secondary structure, wherein the genomes are characterized in that they comprise at a first site a first heterologous nucleotide sequence and at a second site a second heterologous nucleotide sequence that is substantially complementary to the first heterologous nucleotide sequence wherein the first and second sites are spaced from each other to permit annealing between the 20 first and second heterologous nucleotide sequences. [0013] In a related aspect, the present invention provides recombinant single stranded, circular hepatitis delta virus (HDV) RNA genomes, comprising a first portion and a second portion, wherein the first portion comprises in operable connection: (1) a promoter; (2) an open reading frame (ORF) for a hepatitis delta antigen (HDAg); (3) a 25 polyadenylation signal; (4) a HDV ribozyme; and (5) a first heterologous nucleotide sequence, and wherein the second portion is substantially complementary to the first portion so as to permit annealing between the portions. Suitably, the annealing between the portion confers a rod-like secondary structure on the genome. [0014] In some embodiments, the first heterologous nucleotide sequence 30 comprises a nucleotide sequence that is only transcribed into RNA (e.g., a non-coding sequence, illustrative examples of which include functional RNA molecules such as rRNA, tRNA, RNAi, ribozymes and antisense RNA). In other embodiments, the first -3heterologous nucleotide sequence comprises a nucleotide sequence that is both transcribed into mRNA and translated into a polypeptide. Thus, the present invention encompasses embodiments in which the first heterologous nucleotide sequence comprises a coding sequence for an exogenous polypeptide. Suitably, the exogenous 5 polypeptide is selected from a polypeptide of a pathogenic organism (e.g., other than the HDAg), an alloantigen, an autoantigen, a cancer or tumor antigen or any other polypeptide that has therapeutic activity. In specific embodiments, the exogenous polypeptide is or comprises a cytokine (e.g., a cytokine that attenuates HDV, illustrative example of which include interferons (IFNs) including type I IFNs such as IFN-3. Thus, 10 the present invention provides recombinant HDV genomes engineered to stably express heterologous nucleotide sequences including cytokine-encoding sequences, which can provide a means of attenuating virulence (i.e., addressing safety concerns) and/or augmenting immunity against or resistance to HDV and optionally HBV or hepatitis C virus (HCV) in a subject (e.g., a human) to which they are administered. In some 15 embodiments, the coding sequence further comprises a nucleotide sequence that encodes a proteolytic cleavage site positioned to facilitate release of the exogenous polypeptide upon proteolytic processing of a precursor polypeptide comprising the exogenous polypeptide and the HDAg. In specific embodiments, the coding sequence comprises a nucleotide sequence encoding a signal peptide (which is suitably upstream 20 of the coding sequence for the exogenous polypeptide) for transit of the exogenous polypeptide to a particular cellular compartment or into an extracellular environment. Suitably, the signal peptide directs translocation of the exogenous polypeptide across an endoplasmic reticulum (ER) membrane within a host cell (e.g., hepatocyte) infected by the virus. In some embodiments, the exogenous polypeptide is exported to the host cell 25 surface, presented on the cell surface as a peptide with a major histocompatibility antigen, secreted from the cell, or remains in the cytoplasm of the cell. [0015] In some embodiments, the first heterologous nucleotide sequence is located downstream of the promoter and upstream of the ORF. In illustrative examples of this type, the first heterologous nucleotide sequence comprises a coding sequence for 30 an exogenous polypeptide, which is operably connected to the promoter, and an internal ribosome entry site (IRES) that is operably connected to the ORF. [0016] In other embodiments, the first heterologous nucleotide sequence is located downstream of the ORF and suitably upstream of the polyadenylation site. In -4illustrative examples of this type, the first heterologous nucleotide sequence comprises an internal ribosome entry site (IRES) operably connected to a coding sequence for an exogenous polypeptide. [0017] In some embodiments, the first heterologous nucleotide sequence 5 comprises a first coding sequence for an exogenous polypeptide and a second coding sequence for a proteolytic cleavage site, wherein the first and second coding sequences are in frame with each other and with the ORF to thereby encode a precursor polypeptide, wherein the proteolytic cleavage site is positioned between the exogenous polypeptide and the HDAg in the precursor polypeptide to facilitate release of the 10 exogenous polypeptide upon proteolytic cleavage of the proteolytic cleavage site. In illustrative examples of this type, the first heterologous nucleotide sequence comprises a first coding sequence for an exogenous polypeptide and a second coding sequence for a so-called "self-cleaving" peptide (e.g., 2A or 2A-like self-cleaving peptide), wherein the first and second coding sequences are in frame with each other and with the ORF. In 15 some of these examples, the first heterologous nucleotide sequence is located downstream of the promoter and upstream of the ORF, and the second coding sequence is downstream of the first coding sequence and upstream of the ORF. In some other examples, the first heterologous nucleotide sequence is located downstream of the ORF, wherein the second coding sequence is upstream of the first coding sequence and 20 downstream of the ORF. [0018] In other embodiments, the first heterologous nucleotide sequence is located downstream of the HDV ribozyme. In illustrative examples of this type, the first heterologous nucleotide sequence is operably connected to another promoter (e.g., a promoter other than the promoter that is operably connected to the ORF). 25 [0019] Suitably, an operably connected promoter in the recombinant genome is a DNA dependent RNA polymerase (e.g., RNA polymerase I, II or III) promoter, illustrative examples of which include native or wild-type HDV promoters. [0020] In some embodiments, the first heterologous nucleotide sequence has a G/C nucleotide content that substantially accords with the G/C content of the HDV 30 genome, usually between about 55% and about 65% (e.g., about 60%). -5- [0021] In some embodiments, the first heterologous nucleotide sequence has at least about 50% (and at least 51% to at least 99% and all integer percentages in between) sequence identity to the second heterologous nucleotide sequence. [0022] In another aspect, the present invention provides methods for 5 producing a recombinant single-stranded, circular hepatitis delta virus (HDV) RNA genome. These methods generally comprise, consist or consist essentially of: providing a parent single-stranded, circular HDV RNA genome, which comprises in operable connection: a promoter; an open reading frame (ORF) for a hepatitis delta antigen (HDAg); a polyadenylation signal; and a HDV ribozyme, and which has substantially 10 complementary portions that anneal to one another and confer a rod-like secondary structure on the parent genome, and inserting into the parent genome at a first site a first heterologous nucleotide sequence and at a second site a second heterologous nucleotide sequence that is substantially complementary to the first heterologous nucleotide sequence to form the recombinant HDV genome, wherein the first and second sites are 15 spaced from each other in the recombinant genome to permit annealing between the first and second heterologous nucleotide sequences. [0023] Suitably, the methods comprise inserting the first and second heterologous nucleotide sequences such that they do not interfere or impair annealing of the complementary portions of the parent genome. 20 [0024] In some embodiments, the methods comprise inserting the first heterologous nucleotide sequence downstream of the promoter and upstream of the ORF and inserting the second heterologous nucleotide sequence downstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the ORF and upstream of the nucleotide sequence of the parent genome that 25 is substantially complementary and anneals to the promoter. [0025] In other embodiments, the methods comprise inserting the first heterologous nucleotide sequence downstream of the ORF and upstream of the polyadenylation signal and inserting the second heterologous nucleotide sequence downstream of the nucleotide sequence of the parent genome that is substantially 30 complementary and anneals to the polyadenylation signal and upstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the ORF. -6- [0026] In still other embodiments, the methods comprise inserting the first heterologous nucleotide sequence downstream of the ribozyme and upstream of portions of the parent genome that are substantially complementary and anneal to each other and inserting the second heterologous nucleotide sequence downstream of those 5 portions and upstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the ribozyme. [0027] In some embodiments, the first heterologous nucleotide sequence has at least 50% (and at least 51% to at least 99% and all integer percentages in between) sequence identity to the second heterologous nucleotide sequence. 10 [0028] In some embodiments, the methods further comprise modifying the G/C content of the first and second heterologous nucleotide sequences to substantially accord with the G/C content of the parent genome. In representative examples of this type, the G/C content of the first and second heterologous nucleotide sequences is modified so that it is between about 55% to about 65% (e.g., about 60%). 15 [0029] Yet another aspect of the present invention provides nucleic acid molecules (e.g., a DNA molecule such as a cDNA molecule) comprising, consisting or consisting essentially of a sequence corresponding to a recombinant HDV genome as broadly described above and elsewhere herein or to an antigenome thereof. Suitably, the nucleic acid molecules are in isolated form. 20 [0030] Still another aspect of the present invention provides vectors comprising, consisting or consisting essentially of a nucleic acid molecule as broadly described above and elsewhere herein. [0031] In a further aspect of the present invention a recombinant hepatitis delta virus (HDV) is provided, comprising, consisting or consisting essentially of a 25 recombinant genome as broadly described above and elsewhere herein. Suitably, the HDV is in isolated form. [0032] Another aspect of the present invention provides pharmaceutical compositions comprising, consisting or consisting essentially of a recombinant HDV as broadly described above and elsewhere herein, and a pharmaceutically acceptable 30 excipient, diluent or carrier. -7- [0033] Still another aspect of the present invention provides immunomodulating compositions comprising, consisting or consisting essentially of a recombinant HDV as broadly described above and elsewhere herein, and optionally an adjuvant or immunostimulant. 5 [0034] In a further aspect, the present invention provides methods for eliciting an immune response to a hepatitis delta virus (HDV) in a subject (e.g., a human). These methods generally comprise, consist or consist essentially of administering to the subject an effective amount of a recombinant HDV as broadly described above and elsewhere herein so as to elicit an immune response to the HDV. 10 [0035] In a related aspect, the present invention provides methods for treating or preventing a hepatitis delta virus (HDV) infection in a subject (e.g., a human). These methods generally comprise, consist or consist essentially of administering an effective amount of a recombinant HDV as broadly described above and elsewhere herein to the subject. 15 [0036] In some embodiments, the first heterologous nucleotide sequence comprises a cytokine-encoding sequence, including an interferon-encoding sequence, which is useful, for example, in the treatment of hepatitis virus infections, including HDV, HBV and/or HCV infections. Thus, in another aspect, the present invention provides methods for treating or preventing a hepatitis infection in a subject (e.g., a 20 human). These methods generally comprise, consist or consist essentially of administering an effective amount of a recombinant HDV as broadly described above and elsewhere herein to the subject, wherein the first heterologous nucleotide sequence comprises a coding sequence for a cytokine (e.g., one that codes for a type I IFN such as IFN-, a type II IFN such as IFN-y or a type III IFN such as IFN-A). 25 [0037] In another related aspect, the present invention provides a recombinant hepatitis delta virus (HDV) as broadly described above and elsewhere herein, or a composition as broadly described above and elsewhere herein, for use in eliciting an immune response to a HDV in a subject (e.g., a human). [0038] In still another aspect of the present invention, methods are provided 30 for eliciting an immune response to an exogenous polypeptide in a subject (e.g., a human). These methods generally comprise, consist or consist essentially of administering a recombinant hepatitis delta virus (HDV) as broadly described above and -8elsewhere herein to the subject so as to elicit an immune response to the exogenous polypeptide. In non-limiting examples, the exogenous polypeptide is an antigen of the subject or an antigen of a microorganism (e.g., bacteria, protozoa, viruses for example other than the HDV such as hepatitis B virus (HBV) and hepatitis C virus (HCV) and 5 used to generate the recombinant HDV of the invention, yeast, fungi, and the like). [0039] In a related aspect, the present invention provides a recombinant hepatitis delta virus (HDV) as broadly described above and elsewhere herein, or a composition as broadly described above and elsewhere herein, for use in preventing or treating an infection by a pathogen (e.g., other than the HDV used to generate the 10 recombinant HDV of the invention) in a subject (e.g., a human). [0040] Another aspect of the present invention provides methods for delivering an exogenous polypeptide having therapeutic activity to a subject (e.g., a human). These methods generally comprise, consist or consist essentially of administering a hepatitis delta virus (HDV) as broadly described above and elsewhere 15 herein to the subject, whereby the exogenous polypeptide is produced in a host cell of the subject. In illustrative examples of this type, the host cell is a hepatocyte. The therapeutic polypeptide may remain inside the cell, become associated with a cell membrane, or may be secreted from the cell. [0041] Yet another aspect of the present invention provides methods for 20 producing an exogenous polypeptide in a host cell (e.g., a vertebrate host cell). These methods generally comprise, consist or consist of contacting a susceptible host cell with a recombinant hepatitis delta virus (HDV) composition as broadly described above and elsewhere herein, wherein the first heterologous nucleotide sequence comprises a coding sequence for the exogenous polypeptide, and culturing the host cell for a period 25 of time to allow production of the exogenous polypeptide by the host cell. Suitably, the methods further comprise purifying the exogenous polypeptide. -9- BRIEF DESCRIPTION OF THE DRAWINGS [0042] Preferred embodiments of the present invention are described infra, by way of example only, with reference to the accompanying drawings wherein: [0043] Figure 1 is a schematic representation showing a wild-type hepatitis 5 delta virus (HDV) genome, anti-genome and mRNA. The single-stranded RNA genome/ anti-genome is highly self-complementary and forms a 'rod-like' secondary structure. Characteristic features of the anti-genomic RNA (top panel) include a putative promoter (pro) sequence upstream of the open reading frame for the short (S) and long (L) form of the hepatitis delta antigen (HDAg), a polyadenylation signal (poly A) and 10 the anti-genomic ribozyme (ribo) sequence; features of the genomic RNA (middle panel) include a promoter sequence (pro) and the genomic ribozyme (ribo) sequence. HDV mRNAs (bottom panel) feature a 5'-cap structure (Cap) and a poly A tail (zigzag line). The asterisk indicates the position of the editing site that, if edited, extends the HDAg open reading frame by 19 codons and switches the expression from S to L. Note 15 that not all elements are drawn to scale. [0044] Figure 2 is a schematic representation showing the recombinant HDV genome rHDV-hulFNbeta-JRES-HDAg. The heterologous nucleotide sequence of interest, which comprises a human interferon-beta coding sequence (huIFN-) and an internal ribosome entry site (IRES), is inserted between the HDV promoter (pro) 20 sequence and the hepatitis delta antigen (HDSAg) open reading frame. To maintain the 'rod-like' secondary structure of the viral genome, an additional, 'stabilizing', partially complementary sequence has been inserted opposite the first insertion. SS, signal sequence; asterisk, editing site. [0045] Figure 3 is schematic representation showing an illustration of the 25 RNA secondary structures of the HDV genome. RNA sequences were analyzed using RNAfold (http://rna. tbi.univie.ac.at). Predicted minimum free energy structures and base pair probabilities are shown for (a) the parental, wild-type HDV genome, (b) a modified genome into which the human IFN-beta coding sequence has been inserted upstream of the HDSAg open reading frame, a manipulation that destroys the typical 30 'rod-like' structure of the genome (c) a modified genome that contains the IFN sequence described above and partially complementary, 'stabilizing' sequences which restore the 'rod-like' RNA structure; and (d) a modified genome that contains the IFN - 10 sequence, the EMCV IRES sequence and partially complementary, 'stabilizing' sequences. Note that the RNA secondary structure in (d) corresponds to the schematic representation rHDV-huIFNbeta-IRES-HDAg shown in Figure 2. [0046] Figure 4 is photographic representation showing the recombinant 5 HDV genome rHDV-huIFNbeta-IRES-HDAg construct is replication competent. COS 7 cells were transfected with plasmids encoding recombinant HDV genomes and/ or helper plasmids providing HDAg in trans. Total RNA was extracted 6 days after transfection, cDNA synthesis was performed using a genomic-specific primer, and PCR was performed using primers binding to anti-genomic-specific primers flanking the 10 insertion site for the IFN gene. Lane 1, co-transfection of helper plasmids pJC126.S/B and pJC126.S/N; lane 2, pJC126 (encoding wild-type rHDV); lane 3, pJC126S/B and pJC 126.IFN.IRES (encoding rHDV-huIFNbeta-IRES-HDAg); lane 4, pJC 126S/N and pJC126.IFN.IRES; lane 5, pJC126. S/B and pJC126.dellO (replication-deficient HDV mutant with a frame shifting deletion in HDAg); lane 6, pJC 126.S/N and pJC126del10. 15 Grey triangles, 0.7 and 1.7 kb amplicons representing wild-type and IFN co-expressing recombinant HDV genomes, respectively. [0047] Figure 5 is schematic representation showing another embodiment of a recombinant HDV genome, rHDV-HDAg-IRES-huIFNbeta. An internal ribosome entry site (IRES) and the sequence of interest - here exemplified by the human 20 interferon-beta coding sequence (huIFN-3) - have been inserted between the hepatitis delta antigen (HDSAg) open reading frame and the polyadenylation signal (poly A). To maintain the 'rod-like' secondary structure of the viral genome, an additional, 'stabilizing', partially complementary sequence has been inserted opposite the first insertion. SS, signal sequence; asterisk, editing site. 25 [0048] Figure 6 is schematic representation showing another embodiment of a recombinant HDV genome, rHDV-HDAg-2A-huIFNbeta. The sequence of interest here exemplified by the human interferon-beta coding sequence (huIFN-3) - has been fused to a '2A-like' motif (2A) and inserted (in-frame) immediately after the hepatitis delta antigen (HDSAg) coding sequence. To maintain the 'rod-like' secondary structure 30 of the viral genome, an additional, 'stabilizing', partially complementary sequence has been inserted opposite the first insertion. SS, signal sequence; asterisk, editing site. - 11 - [0049] Figure 7 is schematic representation showing a further embodiment of a recombinant HDV genome, rHDV-HDAg-ribo-insertion (example No. 4). The region between the anti-genomic ribozyme and the tip of the 'rod' is another potential site for inserting sequences/ genes of interest (not further specified in this example). To 5 maintain the 'rod-like' secondary structure of the viral genome, an additional, 'stabilizing', partially complementary sequence has been inserted opposite the first insertion. SS, signal sequence; asterisk, editing site. [0050] Some figures and text contain color representations or entities. Color illustrations are available from the Applicant upon request or from an appropriate Patent 10 Office. A fee may be imposed if obtained from a Patent Office. - 12 - DETAILED DESCRIPTION OF THE INVENTION 1. Definitions [0051] Unless defined otherwise, all technical and scientific terms used 5 herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. For the purposes of the present invention, the following terms are defined below. 10 [0052] The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element. Thus, for example, the term "virus" also includes a plurality of viruses. [0053] As used herein, "and/or" refers to and encompasses any and all 15 possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (or). [0054] The terms "antigen" and "epitope" are well understood in the art and refer to the portion of a macromolecule which is specifically recognized by a component of the immune system, e.g., an antibody or a T-cell antigen receptor. 20 Epitopes are recognized by antibodies in solution, e.g., free from other molecules. Epitopes are recognized by T-cell antigen receptor when the epitope is associated with a class I or class II major histocompatibility complex molecule. A "CTL epitope" is an epitope recognized by a cytotoxic T lymphocyte (usually a CD8' cell) when the epitope is presented on a cell surface in association with an MHC Class I molecule. 25 [0055] The term "antigenome" means a positive sense viral RNA molecule or DNA molecule complementary to the entire negative sense single stranded viral RNA genome. [0056] An "allergen" refers to a substance that can induce an allergic or asthmatic response in a susceptible subject. 30 [0057] By "about" is meant a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, position or length that varies by as much - 13 - 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 % to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, position or length. [0058] It will be understood that the term "between" when used in reference to a range of numerical values encompasses the numerical values at each endpoint of the 5 range. For example, a nucleotide sequence of between 10 and 20 nucleotides in length is inclusive of a nucleotide sequence of 10 nucleotides in length and a nucleotide sequence of 20 residues in length. [0059] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly 10 dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, 15 ranges excluding either both of those included limits are also included in the invention. [0060] "Attenuation" or "attenuated" as used herein means a reduction of viral virulence. Virulence is defined as the ability of a virus to cause disease in a particular host. Thus the term "attenuated" is synonymous with "less pathogenic" or sometimes with "apathogenic". 20 [0061] It will be understood that the term "between" when used in reference to a range of numerical values encompasses the numerical values at each endpoint of the range. For example, a nucleotide sequence of between 10 and 20 nucleotides in length is inclusive of a nucleotide of 10 residues in length and a nucleotide of 20 residues in length. 25 [0062] As used herein, the term "cis-acting sequence" or "cis-regulatory region" or similar term shall be taken to mean any sequence of nucleotides which is derived from an expressible genetic sequence wherein the expression of the genetic sequence is regulated, at least in part, by the sequence of nucleotides. Those skilled in the art will be aware that a cis-regulatory region may be capable of activating, silencing, 30 enhancing, repressing or otherwise altering the level of expression and/or cell-type specificity and/or developmental specificity of any structural gene sequence. - 14 - [0063] The term "cistron" refers to a section of DNA or RNA that contains the genetic codes for a single polypeptide or a protein, and may function as a hereditary unit. Thus, the term "bicistronic" refers to the existence in the recombinant viruses of the invention of two unrelated cistrons which are expressed from a single viral 5 transcriptional unit. One cistron may comprise an open reading frame of the virus and the other cistron may comprise a coding sequence for an exogenous polypeptide. [0064] By "coding sequence" is meant any nucleic acid sequence that contributes to the code for the polypeptide product of a gene. By contrast, the term "non-coding sequence" refers to any nucleic acid sequence that does not contribute to 10 the code for the polypeptide product of a gene. [0065] Throughout this specification, unless the context requires otherwise, the words "comprise," "comprises" and "comprising" will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements. Thus, use of the term 15 "comprising" and the like indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present. By "consisting of' is meant including, and limited to, whatever follows the phrase "consisting of'. Thus, the phrase "consisting of' indicates that the listed elements are required or mandatory, and that no other elements may be present. By "consisting essentially of" is meant 20 including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase "consisting essentially of' indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of 25 the listed elements. [0066] By "control element" or "control sequence" is meant nucleic acid sequences (e.g., DNA) necessary for expression of an operably linked coding sequence in a particular host cell. The control sequences that are suitable for prokaryotic cells for example, include a promoter, and optionally a cis-acting sequence such as an operator 30 sequence and a ribosome binding site. Control sequences that are suitable for eukaryotic cells include transcriptional control sequences such as promoters, polyadenylation signals, transcriptional enhancers, translational control sequences such as translational - 15 enhancers and internal ribosome binding sites (IRES), nucleic acid sequences that modulate mRNA stability, as well as targeting sequences that target a product encoded by a transcribed polynucleotide to an intracellular compartment within a cell or to the extracellular environment. 5 [0067] By "corresponds to" or "corresponding to" is meant a nucleic acid sequence that displays substantial sequence identity to a reference nucleic acid sequence (e.g., at least about 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 97, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even up to 100% sequence identity to all or a 10 portion of the reference nucleic acid sequence) or an amino acid sequence that displays substantial sequence similarity or identity to a reference amino acid sequence (e.g., at least 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 97, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even up to 100% sequence similarity or identity to all or a 15 portion of the reference amino acid sequence). [0068] By "effective amount", in the context of treating or preventing a condition or for modulating an immune response to a target antigen or organism is meant the administration of an amount of an agent (e.g., a recombinant virus) or composition to an individual in need of such treatment or prophylaxis, either in a single 20 dose or as part of a series, that is effective for the prevention of incurring a symptom, holding in check such symptoms, and/or treating existing symptoms, of that condition or for modulating the immune response to the target antigen or organism. The effective amount will vary depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated, the formulation of the 25 composition, the assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. [0069] It will be understood that "eliciting" or "inducing" an immune response as contemplated herein includes stimulating an immune response and/or 30 enhancing a previously existing immune response. [0070] As used herein, the terms "encode," "encoding" and the like refer to the capacity of a nucleic acid to provide for another nucleic acid or a polypeptide. For - 16 example, a nucleic acid sequence is said to "encode" a polypeptide if it can be transcribed and/or translated to produce the polypeptide or if it can be processed into a form that can be transcribed and/or translated to produce the polypeptide. Such a nucleic acid sequence may include a coding sequence or both a coding sequence and a non 5 coding sequence. Thus, the terms "encode," "encoding" and the like include an RNA product resulting from transcription of a DNA molecule, a protein resulting from translation of an RNA molecule, a protein resulting from transcription of a DNA molecule to form an RNA product and the subsequent translation of the RNA product, or a protein resulting from transcription of a DNA molecule to provide an RNA product, 10 processing of the RNA product to provide a processed RNA product (e.g., mRNA) and the subsequent translation of the processed RNA product. [0071] The term "endogenous" refers to a gene or nucleic acid sequence or segment that is normally found in a host organism. [0072] The term "expression" with respect to a gene sequence refers to 15 transcription of the gene and, as appropriate, translation of the resulting mRNA transcript to a protein. Thus, as will be clear from the context, expression of a coding sequence results from transcription and translation of the coding sequence. Conversely, expression of a non-coding sequence results from the transcription of the non-coding sequence. 20 [0073] As used herein, it will be understood that the term "hepatitis delta virus" or "HDV" encompasses all viruses within the Deltavirus genus, including HDV as classified by the International Committee on Taxonomy of Viruses (ICTV). [0074] The term "gene" as used herein refers to any and all discrete coding regions of a genome, as well as associated non-coding and regulatory regions. The gene 25 is also intended to mean an open reading frame encoding one or more specific polypeptides, and optionally comprising one or more introns, and adjacent 5' and 3' non coding nucleotide sequences involved in the regulation of expression. In this regard, the gene may further comprise control signals such as promoters, enhancers, termination and/or polyadenylation signals that are naturally associated with a given gene, or 30 heterologous control signals. Accordingly, the term "gene" includes and encompasses a nucleic acid molecule capable of being used to produce mRNA, antisense RNA, siRNA, - 17 shRNA, miRNA and the like. Genes may or may not be capable of being used to produce a functional protein. Genes can include both coding and non-coding regions. [0075] The term "heterologous nucleotide sequence" is used herein to describe genetic material that has been or is about to be artificially introduced into a 5 genome of a host organism and that is transmitted to the progeny of that host. The heterologous nucleotide sequence will typically comprise a polynucleotide that is capable of being transcribed into RNA and optionally, translated and/or expressed under appropriate conditions. In some embodiments, it confers a desired property to the recombinant HDV (e.g., attenuation) into which it is introduced, or otherwise leads to a 10 desired therapeutic or diagnostic outcome. In some embodiments, it is transcribed into a molecule that interferes with transcription or translation (e.g., antisense molecule) or mediates RNA interference (e.g., siRNA or shRNA). In some embodiments, the heterologous nucleotide sequence comprises a plurality of coding sequences, which in illustrative examples encode the same exogenous polypeptide or different exogenous 15 polypeptides. [0076] The terms "heterologous polypeptide," "foreign polypeptide" and "exogenous polypeptide" are used interchangeably to refer to any peptide or polypeptide which is encoded by a heterologous nucleotide sequence," "foreign nucleotide sequence" and "exogenous nucleotide sequence," as defined above. 20 [0077] The term "host cell" refers to a cell into which a vector including a recombinant HDV of the invention is introduced. Host cells of the invention include, but need not be limited to, bacterial, yeast, animal (including vertebrate animals falling within the scope of the term "subject" as defined herein, an illustrative example host cell of which includes a hepatocyte ) insect and plant cells. Host cells can be unicellular, 25 or can be grown in tissue culture as liquid cultures, monolayers or the like. Host cells may also be derived directly or indirectly from tissues or may exist within an organism including animals. [0078] As used herein, the term "immunogenic" when used in the context of a given agent such as, for example, a nucleotide sequence, polypeptide, an heterologous 30 nucleotide sequence, an heterologous polypeptide, an antigen, or an epitope, means that the agent has a capability to induce an immune response, enhance an existing immune response, or alter an existing immune response, either alone, or acting in combination - 18 with other agent(s). The immune response may include a humoral and/or cellular immune response in a subject. As used herein, "antigenic amino acid sequence," "antigenic polypeptide," or "antigenic peptide" means an amino acid sequence that, either alone or in association with an accessory molecule (e.g., a class I or class II major 5 histocompatibility antigen molecule), can elicit an immune response in a subject. [0079] It will be understood that "inducing" an immune response as contemplated herein includes eliciting or stimulating an immune response and/or enhancing a previously existing immune response. [0080] As used herein, the term "internal ribosomal entry site" or "IRES" 10 refers to a viral, cellular, or synthetic (e.g., a recombinant) nucleotide sequence which allows for initiation of translation of an mRNA at a site internal to a coding region within the same mRNA or at a site 3' of the 5' end of the mRNA, to provide for translation of an operably linked coding region located downstream of (i.e., 3' of) the internal ribosomal entry site. This makes translation independent of the 5' cap structure, 15 and independent of the 5' end of the mRNA. An IRES sequence provides necessary cis acting sequences required for initiation of translation of an operably linked coding region. [0081] As used herein the term "isolated" is meant to describe a compound of interest (e.g., a recombinant virus, a nucleic acid molecule such as a genome, a 20 polypeptide, etc.) that is in an environment different from that in which the compound naturally occurs. "Isolated" is meant to include compounds that are within samples that are substantially enriched for the compound of interest and/or in which the compound of interest is partially or substantially purified. [0082] As used herein, the term "live virus" refers to a virus that retains the 25 ability of infecting and replicating in an appropriate subject or host cell. [0083] The term "operably connected" or "operably linked" as used herein refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For example, a transcriptional control sequence (e.g., a promoter) "operably linked" to a coding sequence refers to 30 positioning and/or orientation of the transcriptional control sequence relative to the coding sequence to permit expression of the coding sequence under conditions compatible with the transcriptional control sequence. Alternatively, "operably - 19 connecting" an heterologous nucleotide sequence to the ORF of a HDV encompasses positioning and/or orientation of the heterologous nucleotide sequence relative to the HDV ORF so that (1) the heterologous nucleotide sequence and the ORF are transcribed together to form a single chimeric transcript and optionally (2) if the heterologous 5 nucleotide sequence itself comprises a coding sequence, the coding sequence of the heterologous nucleotide sequence is 'in-frame' with the HDV ORF to produce a chimeric open reading frame comprising the coding sequence of the heterologous nucleotide sequence and the HDV ORF. In another example, an IRES operably connected to the coding sequence of a heterologous nucleotide sequence refers to 10 positioning and/or orientation of the IRES relative to the coding sequence to permit cap independent translation of the coding sequence. [0084] The terms "open reading frame" and "ORF" refer to the amino acid sequence encoded between translation initiation and termination codons of a coding sequence. The terms "initiation codon" and "termination codon" refer to a unit of three 15 adjacent nucleotides ('codon') in a coding sequence that specifies initiation and chain termination, respectively, of protein synthesis (mRNA translation). [0085] As used herein, the term "parent virus" will be understood to be a reference to a virus that is modified to incorporate heterologous genetic material to form a recombinant virus of the present invention. 20 [0086] The terms "polynucleotide," "polynucleotide sequence," "nucleotide sequence," "nucleic acid" or "nucleic acid sequence as used herein designate mRNA, RNA, cRNA, cDNA or DNA. The term typically refers to polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single and double 25 stranded forms of RNA or DNA. [0087] "Polypeptide," "peptide," "protein" and "proteinaceous molecule" are used interchangeably herein to refer to molecules comprising or consisting of a polymer of amino acid residues and to variants and synthetic analogues of the same. Thus, these terms apply to amino acid polymers in which one or more amino acid residues are 30 synthetic non-naturally occurring amino acids, such as a chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally-occurring amino acid polymers. This term also includes within its scope two or more complementing or - 20 interactive polypeptides comprising different parts or portions (e.g., polypeptide domains, polypeptide chains etc.) of a luciferase polypeptide of the present invention, wherein the individual complementing polypeptides together reconstitute the activity of the different parts or portions to form a functional luciferase polypeptide. Such 5 complementing polypeptides are used routinely in protein complementation assays, which are well known to persons skilled in the art. [0088] As used herein the term "recombinant" as applied to "nucleic acid molecules," "polynucleotides" and the like is understood to mean artificial nucleic acid structures (i.e., non-replicating cDNA or RNA; or replicons, self-replicating cDNA or 10 RNA) which can be transcribed and/or translated in host cells or cell-free systems described herein. Recombinant nucleic acid molecules or polynucleotides may be inserted into a vector. Non-viral vectors such as plasmid expression vectors or viral vectors may be used. The kind of vectors and the technique of insertion of the nucleic acid construct according to this invention is known to the artisan. A nucleic acid 15 molecule or polynucleotide according to the invention does not occur in nature in the arrangement described by the present invention. In other words, an heterologous nucleotide sequence is not naturally combined with elements of a parent virus genome (e.g., promoter, ORF, polyadenylation signal, ribozyme). [0089] As used herein, the term "recombinant virus" will be understood to be 20 a reference to a "parent virus" comprising at least one heterologous nucleotide sequence. [0090] The term "self-cleaving peptide" facilitates co-translational separation of a nascent polypeptide chain into two independent parts. [0091] The term "sequence identity" as used herein refers to the extent that 25 sequences are identical on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, I) or the identical amino acid residue (e.g., Ala, Pro, Ser, Thr, 30 Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., - 21 the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For the purposes of the present invention, "sequence identity" will be understood to mean the "match percentage" calculated by the DNASIS computer program (Version 2.5 for windows; available from Hitachi Software engineering Co., 5 Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software. [0092] The terms "signal sequence" or "signal peptide refers to a short (about 3 to about 60 amino acids long) peptide that directs co- or post-translational transport of a protein from the cytosol to certain organelles such as the nucleus, mitochondrial 10 matrix, and endoplasmic reticulum, for example. For proteins having an ER targeting signal peptide, the signal peptides are typically cleaved from the precursor form by signal peptidase after the proteins are transported to the ER, and the resulting proteins move along the secretory pathway to their intracellular (e.g., the Golgi apparatus, cell membrane or cell wall) or extracellular locations. "ER targeting signal peptides," as 15 used herein include amino-terminal hydrophobic sequences which are usually enzymatically removed following the insertion of part or all of the protein through the ER membrane into the lumen of the ER. Thus, it is known in the art that a signal precursor form of a sequence can be present as part of a precursor form of a protein, but will generally be absent from the mature form of the protein. When a protein is said to 20 comprise an ER targeting signal sequence, it is to be understood that, although a precursor form of the protein does contain the signal sequence, a mature form of the protein will likely not contain the signal sequence. Examples of ER targeting signal peptides or sequences that are functional in mammalian cells include the following: the signal sequence for interleukin-7 (IL-7) described in U.S. Patent No. 4,965,195; the 25 signal sequence for interleukin-2 receptor described in Cosman et al. ((1984), Nature 312:768); the interleukin-4 receptor signal peptide described in EP Patent No. 0 367 566; the type I interleukin-1 receptor signal sequence described in U.S. Patent No. 4,968,607; the type II interleukin-1 receptor signal peptide described in EP Patent No. 0 460 846; the signal sequence of human IgG (METDTLLLWVLLLWVPGSTG); and the 30 signal sequence of human growth hormone (MATGSRTSLLLAFGLLCLPWLQEGSA). Many other ER-targeting signal sequences are known in the art, including ones from prokaryotes (e.g., viruses), insects (copepods, - 22 ostracods, etc.), reptilians and avians as well as artificial ER targeting signal sequences such as: LLLVGILFWA and MLLLLLLLLPQAQA. [0093] "Similarity" refers to the percentage number of amino acids that are identical or constitute conservative substitutions as defined in Table A below. Similarity 5 may be determined using sequence comparison programs such as GAP (Deveraux et al. 1984, Nucleic Acids Research12: 387-395). In this way, sequences of a similar or substantially different length to those cited herein might be compared by insertion of gaps into the alignment, such gaps being determined, for example, by the comparison algorithm used by GAP. 10 TABLE A: EXEMPLARY CONSERVATIVE AMINO ACID SUBSTITUTIONS Original Residue Exemplary Substitutions Ala Ser Arg Lys Asn Gln, His Asp Glu Cys Ser Gln Asn Glu Asp Gly Pro His Asn, Gin Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile, Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp, Phe - 23 - Val Ile, Leu [0094] Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include "reference sequence," "comparison window", "sequence identity," "percentage of sequence identity" and "substantial identity". A 5 "reference sequence" is at least 12 but frequently 15 to 18 and often at least 25 monomer units, inclusive of nucleotides and amino acid residues, in length. Because two polynucleotides may each comprise (1) a sequence (i.e., only a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons 10 between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window" refers to a conceptual segment of at least 6 contiguous positions, usually about 50 to about 100, more usually about 100 to about 150 in which a sequence is compared to a reference sequence of the same 15 number of contiguous positions after the two sequences are optimally aligned. The comparison window may comprise additions or deletions (i.e., gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerized implementations 20 of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e., resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as for 25 example disclosed by Altschul et al., 1997, Nucl. Acids Res.25:3389. A detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel et al., "Current Protocols in Molecular Biology", John Wiley & Sons Inc, 1994-1998, Chapter 15. [0095] The terms "subject," "patient," "host" or "individual" used interchangeably herein, refer to any subject, particularly a vertebrate subject, and even 30 more particularly a mammalian subject, for whom therapy or prophylaxis is desired. Suitable vertebrate animals that fall within the scope of the invention include, but are - 24 not restricted to, any member of the subphylum Chordata including primates (e.g., humans, monkeys and apes, and includes species of monkeys such from the genus Macaca (e.g., cynomologus monkeys such as Macaca fascicularis, and/or rhesus monkeys (Macaca mulatta)) and baboon (Papio ursinus), as well as marmosets (species 5 from the genus Callithrix), squirrel monkeys (species from the genus Saimiri) and tamarins (species from the genus Saguinus), as well as species of apes such as chimpanzees (Pan troglodytes)), rodents (e.g., mice rats, guinea pigs), lagomorphs (e.g., rabbits, hares), bovines (e.g., cattle), ovines (e.g., sheep), caprines (e.g., goats), porcines (e.g., pigs), equines (e.g., horses), canines (e.g., dogs), felines (e.g., cats), avians (e.g., 10 chickens, turkeys, ducks, geese, companion birds such as canaries, budgerigars etc.), marine mammals (e.g., dolphins, whales), reptiles (snakes, frogs, lizards etc.), and fish. A preferred subject is a human in need of treatment or prophylaxis of a condition. However, it will be understood that the aforementioned terms do not imply that symptoms are present. 15 [0096] As used herein, the terms "treatment", "treating", and the like, refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease. "Treatment", as used herein, covers any 20 treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease. 25 [0097] As used herein, the term "5' untranslated region" or "5' UTR" refers to a sequence located upstream (i.e., 5') of a coding region. Typically, a 5' UTR is located downstream (i.e., 3') to a promoter region and 5' of a coding region downstream of the promoter region. Thus, such a sequence, while transcribed, is upstream of the translation initiation codon and therefore is generally not translated into a portion of the 30 polypeptide product. [0098] The term "3 untranslated region" or "3 UTR" refers to a nucleotide sequence downstream (i.e., 3') of a coding sequence. It generally extends from the first - 25 nucleotide after the stop codon of a coding sequence to just before the poly(A) tail of the corresponding transcribed mRNA. The Y UTR may contain sequences that regulate translation efficiency, mRNA stability, mRNA targeting and/or polyadenylation. [0099] The terms "wild-type," "native" or "naturally-occurring" as used 5 herein to describe viruses, refer to a genotype of a virus found in nature. [0100] Each embodiment described herein is to be applied mutatis mutandis to each and every embodiment unless specifically stated otherwise. 2. Recombinant Hepatitis Delta Viruses [0101] Despite the potential advantages offered by live recombinant HDVs, 10 to date it has not been possible to stably incorporate foreign or heterologous nucleotide sequences of interest into the genomes of these viruses. The present inventors have surprisingly discovered, however, that stable insertion of a heterologous nucleotide sequence of interest is possible provided the recombinant HDV genome retains or maintains a substantially "rod-like" secondary structure, as for example found in wild 15 type or naturally-occurring HDV genomes. In accordance with the present invention, the rod-like secondary structure of the HDV genome can be retained, maintained or restored by inserting a "stabilizing" heterologous nucleotide sequence generally at a different site in the HDV genome to the one used for inserting the heterologous nucleotide sequence of interest, in which the stabilizing heterologous nucleotide 20 sequence is substantially complementary to the heterologous nucleotide sequence of interest, whereby the heterologous nucleotide sequences are in juxtaposition to permit annealing to each other and to thereby retain, maintain or restore the rod-like secondary structure of the HDV genome. Recombinant HDV genomes constructed according to this strategy are remarkably stable over multiple replication cycles. 25 [0102] Accordingly, the present invention provides a recombinant single stranded, circular HDV RNA genome, which comprises or consists essentially of in operable connection: a promoter; an ORF for a HDAg; a polyadenylation signal; and a HDV ribozyme, wherein the genome comprises substantially complementary portions conferring a rod-like secondary structure, and wherein the genome comprises at a first 30 site a first heterologous nucleotide sequence and at a second site a second heterologous nucleotide sequence that is substantially complementary to the first heterologous nucleotide sequence wherein the first and second sites are spaced from each other to - 26 permit annealing between the first and second heterologous nucleotide sequences. Generally, the HDV genome will comprise in order from 5' to 3', the promoter, the ORF, the polyadenylation signal and the ribozyme. In non-limiting examples, the first site, which defines where the first heterologous nucleotide sequence is inserted into the 5 HDV genome, can be between adjacent genome elements (e.g., between the promoter and the ORF, or between the ORF and the polyadenylation signal or between the polyadenylation signal and the ribozyme or downstream of the ribozyme). The second site, which defines where the second 'stabilizing' heterologous nucleotide sequence is inserted into the HDV genome, will generally be located between portions of the HDV 10 genome that are substantially complementary and anneal to the adjacent elements between which the first heterologous nucleotide sequence is inserted. Suitably, the first and second sites are chosen so that insertion of the first and second heterologous nucleotide sequences into those sites does not interfere or impair annealing of the complementary portions of the parent genome (e.g., so that the rod-like secondary 15 structure of the HDV genome is retained, maintained or restored). [0103] The first and second heterologous nucleotide sequences will generally display at least 50% (and at least 51% to at least 99% and all integer percentages in between) and up to 100% sequence identity to each other to permit annealing therebetween. 20 [0104] It is generally desirable to modify the G/C content of the first and second heterologous nucleotide sequences so that their G/C content is between about 55% to about 65% (e.g., about 60%) to substantially accord with the G/C content of the parent HDV genome and to facilitate annealing between the heterologous nucleotide sequence under the same conditions permitting annealing between substantially 25 complementary portions of the HDV genome. In illustrative examples of this type, if the first heterologous sequence comprises a coding sequence for an exogenous polypeptide, the codon composition of the coding sequence is modified/optimized using the degeneracy of the genetic code so that the G/C content of the coding sequence is substantially in accord with the G/C content of the parent HDV genome. 30 [0105] If desired, in silico analysis may be employed to predict whether the RNA secondary structure of a recombinant HDV genome is likely to adopt a rod-like structure. A representative RNA structure prediction software/algorithm includes - 27 - RNAfold available on the RNAfold Webserver (which is currently operated by the Institute for Theoretical Chemistry, University of Vienna, Austria (http://rna.tbi.univie.ac.at/). Alternative software/algorithms that may be used for analysis include for example: CentroidFold, CentroidHomfold, CONTRAfold, 5 CyloFold, KineFold, Mfold, Pknots, PknotsRG, RNA123, RNAfold, RNAshapes, RNAstructure, Sfold, UNAFold, Crumple, BARNACLE, FARNA, iFoldRNA, MC Fold MC-Sym Pipeline, NAST, RNA123, Carnac, CentroidAlifold, CentroidAlign, CMfinder, CONSAN, Dynalign, FoldalignM, KNetFold, LARA, LocaRNA, MASTR, Murlet, MXSCARNA, PARTS, Pfold, PETfold, PMcomp/PMmulti, R-COFFEE, 10 RNA123, RNAalifold, RNAcast, RNAforester, RNAmine, RNASampler, SCARNA, SimulFold, Stemloc, StrAl, TFold, WAR, Xrate. Illustrative sources for these software/algorithms can be found for example at: http://en.wikipedia.org/wiki/ ListofRNAstructure-predictionsoftware. [0106] In some embodiments, the first heterologous nucleotide sequence is 15 inserted downstream of the promoter and upstream of the ORF and the second heterologous nucleotide sequence is inserted downstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the ORF and upstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the promoter. In non-limiting examples of this type, the 20 first heterologous nucleotide sequence comprises a coding sequence for an exogenous polypeptide, which is operably connected to the promoter, and an internal ribosome entry site (IRES) that is operably connected to the ORF, to define a bicistronic recombinant HDV genome. In other illustrative examples, the first heterologous nucleotide sequence comprises a first coding sequence for an exogenous polypeptide 25 and a second coding sequence for a proteolytic cleavage site, wherein the first and second coding sequences are in frame with each other and with the ORF to thereby encode a precursor polypeptide, wherein the second coding sequence is downstream of the first coding sequence and upstream of the ORF, wherein the proteolytic cleavage site is positioned between the exogenous polypeptide and the HDAg in the precursor 30 polypeptide to facilitate release of the exogenous polypeptide upon proteolytic cleavage of the proteolytic cleavage site. [0107] In other embodiments, the first heterologous nucleotide sequence is inserted downstream of the ORF and upstream of the polyadenylation signal and the - 28 second heterologous nucleotide sequence is inserted downstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the polyadenylation signal and upstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the ORF. In illustrative examples of 5 this type, the first heterologous nucleotide sequence comprises an internal ribosome entry site (IRES) operably connected to a coding sequence for an exogenous polypeptide, to define a bicistronic recombinant HDV genome. In other representative examples, the first heterologous nucleotide sequence comprises a first coding sequence for an exogenous polypeptide and a second coding sequence for a proteolytic cleavage 10 site, wherein the first and second coding sequences are in frame with each other and with the ORF to thereby encode a precursor polypeptide, wherein the second coding sequence is downstream of the ORF and upstream of the first coding sequence, wherein the proteolytic cleavage site is positioned between the exogenous polypeptide and the HDAg in the precursor polypeptide to facilitate release of the exogenous polypeptide 15 upon proteolytic cleavage of the proteolytic cleavage site. [0108] In still other embodiments, the methods comprise inserting the first heterologous nucleotide sequence downstream of the ribozyme and upstream of portions of the parent genome that are substantially complementary and anneal to each other and inserting the second heterologous nucleotide sequence downstream of those 20 portions and upstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the ribozyme. In non-limiting examples of this type, the first heterologous nucleotide sequence is operably connected to another promoter (e.g., a promoter other than the promoter that is operably connected to the ORF) and suitably to another polyadenylation site (e.g., a polyadenylation site other 25 than the polyadenylation site that is operably connected to the ORF). Suitably, an operably connected promoter in the recombinant genome is a DNA dependent RNA polymerase (e.g., RNA polymerase I and/or RNA polymerase II) promoter, illustrative examples of which include native or wild-type HDV promoters. [0109] Suitably, the recombinant viruses are live, attenuated recombinant 30 viruses. In specific embodiments, the recombinant viruses are replication-competent meaning that they are capable of reproducing in a host cell that they have infected suitably in the presence of HBV that has also infected the host cell. - 29 - 2.1 Hepatitis delta viruses [0110] Recombinant viruses of the present invention may be produced by genetic modification of a "parent" virus. The parent virus is modified to incorporate foreign or exogenous genetic material in the form of a heterologous nucleotide sequence 5 to produce the recombinant virus. Accordingly, it will be understood that reference herein to a specific type of recombinant virus (e.g., a "recombinant HDV") denotes a parent virus of the indicated type that has been modified to incorporate foreign or exogenous genetic material. [0111] Although no particular limitation exists regarding the specific type of 10 recombinant HDVs provided herein, the present invention encompasses any recombinant viruses classified within the Deltavirus genus under the International Committee on Taxonomy of Viruses (ICTV). Such "delta viruses" will include any genotype of HDV including, but not limited to, HDV genotypes I, II, III, IV, V, VI and VII. 15 [0112] Non-limiting parent HDV genomes for insertion of heterologous nucleotide sequence according to the present invention are listed in Table B: TABLE B: ILLUSTRATIVE PARENT HDV GENOMES FOR PREPARING RECOMBINANT HDVs GenBank Description Accession No. D01075.1 Hepatitis delta virus genomic RNA, complete genome AM779579.1 Hepatitis delta virus dFr2395 LHD gene for large HD antigen, genomic RNA, strain dFr2395 AM902165.1 Hepatitis delta virus dFr2172 LHD gene for large HD antigen, genomic RNA, strain dFr2172 AM902177.1 Hepatitis delta virus dFr2012 LHD gene for large HD antigen, genomic RNA, strain dFr2012 AM902163.1 Hepatitis delta virus dFr2067 LHD gene for large HD antigen, genomic RNA, strain dFr2067 AM779578.1 Hepatitis delta virus dFr2239b LHD gene for large HD antigen, genomic RNA, strain dFr2239b AM779587.1 Hepatitis delta virus dTk7 LHD gene for large HD antigen, genomic RNA, strain dTk7 - 30 - AM902179.1 Hepatitis delta virus dFr2042 LHD gene for large HD antigen, genomic RNA, strain dFr2042 AM779597.1 Hepatitis delta virus dTk2 LHD gene for large HD antigen, genomic RNA, strain dTk2 AM902172.1 Hepatitis delta virus dFr2264 LHD gene for large HD antigen, genomic RNA, strain dFr2264 M28267.1 Human hepatitis delta virus encoding delta-antigen RNA, complete cds AF098261.1 Hepatitis D virus from Canada, complete genome M55042.1 Hepatitis D virus delta antigen (HDAg) mRNA, complete cds AJ000558.1 Hepatitis D Virus complete genome X0445 1.1 Hepatitis delta virus (HDV) RNA genome M21012.1 Hepatitis delta virus RNA, complete genome AJ307077.1 Hepatitis delta virus complete genome, isolate W5 AM779594.1 Hepatitis delta virus dTk27 LHD gene for large HD antigen, genomic RNA, strain dTk27 AM779586.1 Hepatitis delta virus dTk28 LHD gene for large HD antigen, genomic RNA, strain dTk28 HM046802.1 Hepatitis delta virus isolate JN, complete genome X85253.1 Hepatitis D virus complete genome containing delta antigen ORF AY648956.1 Hepatitis delta virus isolate TW1435#47, complete genome AM779596.1 Hepatitis delta virus dTk21 LHD gene for large HD antigen, genomic RNA, strain dTk21 M92448.1 Hepatitis D virus, 5' end L22066.1 Hepatitis delta virus antigen gene, complete cds, and autocleavage/ligation sites AB118848.1 Hepatitis delta virus DNA, complete genome, strain:Nagasaki(JA-N1) AY648957.1 Hepatitis delta virus isolate TW5132#24, complete genome AM902175.1 Hepatitis delta virus dFr2406 LHD gene for large HD antigen, genomic RNA, strain dFr2406 AM779582.1 Hepatitis delta virus dTk35 LHD gene for large HD antigen, genomic RNA, strain dTk35 AM779591.1 Hepatitis delta virus dTk5 LHD gene for large HD antigen, genomic - 31 - RNA, strain dTk5 AY633627.1 Hepatitis delta virus isolate IR-1, complete genome AF425644.1 Hepatitis D virus isolate TWD2577-66 genotype I, complete genome AF104263.1 Hepatitis D virus strain TW2667, complete genome AY648959.1 Hepatitis delta virus isolate TW3678#25, complete genome AY648958.1 Hepatitis delta virus isolate TW1573#4, complete genome AM779590.1 Hepatitis delta virus dTk38 LHD gene for large HD antigen, genomic RNA, strain dTk38 AM779588.1 Hepatitis delta virus dTk34 LHD gene for large HD antigen, genomic RNA, strain dTk34 AM779581.1 Hepatitis delta virus dTkl LHD gene for large HD antigen, genomic RNA, strain dTkl AM902173.1 Hepatitis delta virus dFr2380 LHD gene for large HD antigen, genomic RNA, strain dFr2380 AM779584.1 Hepatitis delta virus dTk4 LHD gene for large HD antigen, genomic RNA, strain dTk4 AB118849.1 Hepatitis delta virus DNA, complete genome, strain:Nagasaki(JA-N2) AM902166.1 Hepatitis delta virus dFr2189 LHD gene for large HD antigen, genomic RNA, strain dFr2189 X77627.1 Hepatitis D virus genomic RNA for HDAg AM902174.1 Hepatitis delta virus dFr2404 LHD gene for large HD antigen, genomic RNA, strain dFr2404 AM779595.1 Hepatitis delta virus dTkl2 LHD gene for large HD antigen, genomic RNA, strain dTkl2 AM779589.1 Hepatitis delta virus dTk3 LHD gene for large HD antigen, genomic RNA, strain dTk3 HQ005366.1 Hepatitis delta virus isolate 6, complete genome AM779585.1 Hepatitis delta virus dTk6 LHD gene for large HD antigen, genomic RNA, strain dTk6 HQ005369.1 Hepatitis delta virus isolate 4, complete genome HQ00537 1.1 Hepatitis delta virus isolate 2, complete genome HQ005368.1 Hepatitis delta virus isolate 9, complete genome HQ005372.1 Hepatitis delta virus isolate 3, complete genome - 32 - HQ005367.1 Hepatitis delta virus isolate 8, complete genome AM779583.1 Hepatitis delta virus dTklO LHD gene for large HD antigen, genomic RNA, strain dTklO U81989.1 Hepatitis delta virus from Ethiopia genotype IC, complete genome HQ005364.1 Hepatitis delta virus isolate 5, complete genome M58629.1 Hepatitis delta virus large and small antigens (HDAg) gene, complete cds HQ005365.1 Hepatitis delta virus isolate 7, complete genome M84917.1 Hepatitis D virus RNA sequence AM902169.1 Hepatitis delta virus dFr2236 LHD gene for large HD antigen, genomic RNA, strain dFr2236 AM902168.1 Hepatitis delta virus dFr2045 LHD gene for large HD antigen, genomic RNA, strain dFr2045 AM779592.1 Hepatitis delta virus dTk8 LHD gene for large HD antigen, genomic RNA, strain dTk8 AM779577.1 Hepatitis delta virus dFr2284 LHD gene for large HD antigen, genomic RNA, strain dFr2284 HQ005370.1 Hepatitis delta virus isolate 1, complete genome AM779593.1 Hepatitis delta virus dTkl3 LHD gene for large HD antigen, genomic RNA, strain dTkl3 AM902178.1 Hepatitis delta virus dFr204O LHD gene for large HD antigen, genomic RNA, strain dFr204O AM90217 1.1 Hepatitis delta virus dFr2258 LHD gene for large HD antigen, genomic RNA, strain dFr2258 AM902167.1 Hepatitis delta virus dFr2201 LHD gene for large HD antigen, genomic RNA, strain dFr2201 AM902164.1 Hepatitis delta virus dFr2137 LHD gene for large HD antigen, genomic RNA, strain dFr2137 AM779580.1 Hepatitis delta virus dFr2046 LHD gene for large HD antigen, genomic RNA, strain dFr2046 AM902180.1 Hepatitis delta virus dFr2043 LHD gene for large HD antigen, genomic RNA, strain dFr2043 AM779574.1 Hepatitis delta virus dFr508 LHD gene for large HD antigen, genomic RNA, strain dFr508 - 33 - AM779576.1 Hepatitis delta virus dFr2544 LHD gene for large HD antigen, genomic RNA, strain dFr2544 AM902181.1 Hepatitis delta virus dFr2210 LHD gene for large HD antigen, genomic RNA, strain dFr2210 AM902176.1 Hepatitis delta virus dFr2411 LHD gene for large HD antigen, genomic RNA, strain dFr2411 U81988.1 Hepatitis delta virus from Somalia genotype IC, complete genome AM902170.1 Hepatitis delta virus dFr2244 LHD gene for large HD antigen, genomic RNA, strain dFr2244 EF514907.1 Hepatitis delta virus isolate ZA, complete genome EF514906.1 Hepatitis delta virus isolate SO, complete genome AM779575.1 Hepatitis delta virus dFr2119 LHD gene for large HD antigen, genomic RNA, strain dFr2119 EF514903.1 Hepatitis delta virus isolate CB, complete genome EF514904.1 Hepatitis delta virus isolate NK, complete genome EF514905.2 Hepatitis delta virus isolate OA, complete genome S75645.1 HDAg [hepatitis D virus (HDV) hepatitis D virus HDV, Chinese isolate SZ 93, Genomic, 840 nt] AJ309873.1 Hepatitis D Virus partial ag gene for hepatitis delta small antigen, genomic RNA, isolate Yakut-30 AJ309878.1 Hepatitis D Virus partial ag gene for hepatitis delta small antigen, genomic RNA, isolate Yakut-724 AJ309872.1 Hepatitis D Virus partial ag gene for hepatitis delta antigen, genomic RNA, isolate Yakut-12 AJ309871.1 Hepatitis D Virus partial ag gene for hepatitis delta antigen, genomic RNA, isolate Yakut-8 AY526577.1 Hepatitis delta virus small delta antigen gene, complete cds D90191.1 Hepatitis delta virus gene for hypothetical protein, complete cds, isolate: 7/6/89 D90190.1 Hepatitis delta virus gene for hypothetical protein, complete cds, isolate: 9/20/86 AJ309876.1 Hepatitis D Virus partial ag gene for hepatitis delta small antigen, genomic RNA, isolate Yakut-51 AJ309879.1 Hepatitis D Virus partial mRNA for hepatitis delta antigen (ag gene), - 34 isolate Yakut-26 X60193.1 Hepatitis delta virus HDVJS U19598.1 Hepatitis D virus large hepatitis delta antigen (HDAg) gene, complete cds AB 118846.1 Hepatitis delta virus DNA, complete genome, strain:Miyako(JA-M37) AF425645.1 Hepatitis D virus isolate TWD2476-38 genotype Ila, complete genome AY261457.1 Hepatitis D virus isolate TW2479-12s, complete genome DQ519393.2 Hepatitis delta virus genotype I delta antigen gene, complete cds ABi18845.1 Hepatitis delta virus DNA, complete genome, strain:Miyako(JA-M36) [0113] In specific embodiments, the recombinant HDV genome is prepared using the parent HDV RNA genome (-) JC126, which comprises, consists or consists essentially of the nucleotide sequence: 5 [0114] ccugagccaaguuccgagcgaggagacgcggggggaggaucagcucccgag aggggaugucacgguaaagagcauuggaacgucggagaaacuacucccaagaagcaaagagagg ucuuaggaagcggacgagauccccacaacgccggagaaucucuggaaggggaaagaggaaggug gaagaaaaaggggcgggccucccgauccgaggggcccaaucccagaucuggagagcacuccggc ccgaaggguugaguagcacucagagggaggaauccacucggagaugagcagagaaaucaccucc 10 agaggaccccuucagcgaacaagaggcgcuucgagcgguaggaguaagaccauagcgauaggag gagaugcuaggaguagggggagaccgaagcgaggaggaaagcaaagaaagcaacggggcuagcc gguggguguuccgccccccgagaggggacgagugaggcuuaucccggggaacucgacuuaucgu ccccaucuagcgggaccccggacccccuucgaaagugaccggagggggugcugggaacaccggg gaccaguggagccaugggaugcccuucccgaugcucgauuccgacuccccccccaagggucgcc 15 cuggcgggaccccacucugcaggguccgcguuccauccuuucuuaccugauggccggcaugguc ccagccuccucgcuggcgccggcugggcaacauuccgaggggaccguccccucgguaauggcga augggacccacaaaucucucuagauuccgauagagaaucgagagaaaaguggcucucccuuagc cauccgaguggacgugcguccuccuucggaugcccaggucggaccgcgaggagguggagaugcc augccgacccgaagaggaaagaaggacgcgagacgcaaaccugugaguggaaacccgcuuuauc 20 uggggucgacaacucuggggagaaaagggcggaucggcugggaagaguauauccuauggaaauc ccugguuuccccugauguccagccccuccccgguccgagagaagggggacuccgggacucccug cagauuggggacgaagccgcccccgggcgcuccccucgauccaccuucgaggggguucacaccc ccaaccggcgggccggcuacucuucuuucccuucucucgucuuccucggucaaccuccugaguu ccucuucuuccuccuugcugagguucuugccucccgccgauagcugcuucuucuuguucucgag 25 ggccuuccuucgucggugauccugccucuccuugucggugaauccuccccugagaggccucuuc - 35 ccagguccggagucuaccuccaucugguccguucgggcccucuucgccgggggagcccccucuc cauccuuauccuucuuuccgagaauuccuuugauguuccccagccagggauuuucguccucuau cuucuugaguuucuucuuugucuuccggaggucucucucgaguuccucuaacuucuuucuuccg gccacccacugcucgaggaucucuucucucccuccgcgguucuuccucgacucggaccggcuca 5 ucucggcuagaggcggcaguccucaguacucuuacucuuuucuguaaagaggagacugcuggac ucgccgcccgagcccgag [SEQ ID NO:1]. [0115] cDNA is generally used to make the recombinant HDV genome and thus the present invention encompasses the use of a cDNA sequence corresponding to the HDV JC126 strain parent RNA genome, which comprises, consists or consists 10 essentially of the nucleotide sequence: [0116] cctgagccaagttccgagcgaggagacgcggggggaggatcagctcccgag aggggatgtcacggtaaagagcattggaacgtcggagaaactactcccaagaagcaaagagagg tcttaggaagcggacgagatccccacaacgccggagaatctctggaaggggaaagaggaaggtg gaagaaaaaggggcgggcctcccgatccgaggggcccaatcccagatctggagagcactccggc 15 ccgaagggttgagtagcactcagagggaggaatccactcggagatgagcagagaaatcacctcc agaggaccccttcagcgaacaagaggcgcttcgagcggtaggagtaagaccatagcgataggag gagatgctaggagtagggggagaccgaagcgaggaggaaagcaaagaaagcaacggggctagcc ggtgggtgttccgccccccgagaggggacgagtgaggcttatcccggggaactcgacttatcgt ccccatctagcgggaccccggacccccttcgaaagtgaccggagggggtgctgggaacaccggg 20 gaccagtggagccatgggatgcccttcccgatgctcgattccgactccccccccaagggtcgcc ctggcgggaccccactctgcagggtccgcgttccatcctttcttacctgatggccggcatggtc ccagcctcctcgctggcgccggctgggcaacattccgaggggaccgtcccctcggtaatggcga atgggacccacaaatctctctagattccgatagagaatcgagagaaaagtggctctcccttagc catccgagtggacgtgcgtcctccttcggatgcccaggtcggaccgcgaggaggtggagatgcc 25 atgccgacccgaagaggaaagaaggacgcgagacgcaaacctgtgagtggaaacccgctttatc tggggtcgacaactctggggagaaaagggcggatcggctgggaagagtatatcctatggaaatc cctggtttcccctgatgtccagcccctccccggtccgagagaagggggactccgggactccctg cagattggggacgaagccgcccccgggcgctcccctcgatccaccttcgagggggttcacaccc ccaaccggcgggccggctactcttctttcccttctctcgtcttcctcggtcaacctcctgagtt 30 cctcttcttcctccttgctgaggttcttgcctcccgccgatagctgcttcttcttgttctcgag ggccttccttcgtcggtgatcctgcctctccttgtcggtgaatcctcccctgagaggcctcttc ccaggtccggagtctacctccatctggtccgttcgggccctcttcgccgggggagccccctctc catccttatccttctttccgagaattcctttgatgttccccagccagggattttcgtcctctat cttcttgagtttcttctttgtcttccggaggtctctctcgagttcctctaacttctttcttccg 35 gccacccactgctcgaggatctcttctctccctccgcggttcttcctcgactcggaccggctca - 36 tctcggctagaggcggcagtcctcagtactcttactcttttctgtaaagaggagactgctggac tcgccgcccgagcccgag [SEQ ID NO: 2]. [0117] SEQ ID NO:2 differs from the published sequence corresponding to the HDV JC126 strain parent genome (as set out in GenBank Accession No. M21012.1) 5 at 7 positions as follows: [0118] nucleotide 45: A to T [0119] nucleotide 221: T deleted [0120] nucleotide 619: C deleted [0121] nucleotide 840: C to G 10 [0122] nucleotide 1343: G to C [0123] nucleotide 1389: G to C [0124] nucleotide 1633: A to T [0125] As a result the corrected sequence contains only 1677 nucleotides. 2.2 Heterologous nucleotide sequences of interest (HSI) 15 [0126] Recombinant viruses of the present invention comprise a first heterologous nucleotide sequence or interest (HSI), which encompasses any nucleotide sequence inserted into the genome of the parent virus, which does not normally exist or naturally occur in that genome. The HSI may therefore include a sequence that is identical to a sequence in the genome of the parent virus, or, a sequence that differs 20 from sequences in the genome of the parent virus. In certain embodiments, the HSI comprises a nucleotide sequence from a HDV that is different to the parent virus including, but not limited to, different viral strains; and different viral serotypes. The HSI may encode an exogenous transcript product that interferes with transcription or translation (e.g., antisense molecule) or mediates RNA interference (e.g., siRNA or 25 shRNA). Alternatively, or in addition, the HSI may encode an exogenous polypeptide product. [0127] Exogenous polypeptides include polypeptides from any of a variety of pathogenic organisms, including, but not limited to, viruses, bacteria, yeast, fungi, and protozoa; cancer- or tumor-associated antigens; "self' antigens (i.e., autoantigens); - 37 foreign antigens (e.g., alloantigens and allergens) from other than pathogenic organisms; proteins that have a therapeutic activity; and the like. [0128] Where the polypeptide comprises one or more antigenic epitopes, any nucleic acid molecule comprising a nucleotide sequence which encodes a polypeptide 5 which, when produced by a cell infected by a recombinant HDV of the invention, increases an immune response is suitable for use in the present invention. Nucleic acid sequences encoding one or more exogenous polypeptides (e.g., antigens or epitopes) of interest can be included in a recombinant HDV as defined herein. If more than one exogenous antigen or epitope of interest is encoded by the heterologous nucleic acid 10 sequences, they can be antigens or epitopes of a single pathogen or antigens or epitopes from more than one (different) pathogen. In some embodiments, such an organism is a pathogenic microorganism. For example, such an exogenous epitope may be found on bacteria, parasites, viruses, yeast, or fungi that are the causative agents of diseases or disorders. In other embodiments, the antigen is an allergen. In still other embodiments, 15 the antigen is a cancer- or tumor-associated antigen. [0129] Pathogenic viruses include, but are not limited to, Retroviridae (e.g., human immunodeficiency viruses, such as HIV- 1 (also referred to as HTLV-III, LAV or HTLV-II1/LAV, or HIV-III); and other isolates, such as HIV-LP; Picornaviridae (e.g., polio viruses, hepatitis A virus; enteroviruses, human coxsackie viruses, rhinoviruses, 20 echoviruses); Caliciviridae (e.g., strains that cause gastroenteritis, including caliciviruses such as Norwalk virus); Togaviridae (e.g., equine encephalitis viruses, rubella viruses); Flaviridae (e.g., dengue viruses, encephalitis viruses, yellow fever viruses, hepatitis C virus); Coronaviridae (e.g., coronaviruses); Rhabdoviridae (e.g., vesicular stomatitis viruses, rabies viruses); Filoviridae (e.g., ebola viruses); 25 Paramyxoviridae (e.g., parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus); Orthomyxoviridae (e.g., influenza viruses); Bunyaviridae (e.g., Hantaan viruses, orthobunyaviruses, phleboviruses and nairoviruses); Arenaviridae (hemorrhagic fever viruses); Reoviridae (e.g., reoviruses, orbiviruses and rotaviruses); Birnaviridae; Hepadnaviridae (Hepatitis B virus); Parvoviridae (parvoviruses); 30 Papovaviridae (papilloma viruses, polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae (herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV)); Poxviridae (variola viruses, vaccinia viruses, pox viruses); - 38 and Iridoviridae (e.g., African swine fever virus); and unclassified viruses; and astroviruses. [0130] Pathogenic bacteria include, but are not limited to, Helicobacter pyloris, Borelia burgdorferi, Legionella pneumophila, Mycobacteria sps (e.g., M. 5 tuberculosis, M. avium, M. intracellulare, M. kansaii, M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyrogenes (Group A Streptococcus), Streptococcus agalactiae (Group B Streptococcus), Streptococcus (viridans group), Streptococcus faecalis, Streptococcus bovis, Streptococcus (anaerobic spp.), Streptococcus pneumoniae, pathogenic 10 Campylobacter sp., Enterococcus sp., Haemophilus influenzae, Bacillus anthracis, Corynebacterium diphtheriae, Corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, Bacteroides sp., Fusobacterium nucleatum, pathogenic strains of Escherichia coli, Streptobacillus moniliformis, Treponema 15 pallidium, Treponema pertenue, Leptospira, and Actinomyces israelli. [0131] Infectious fungi include, but are not limited to, Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis and Candida albicans. [0132] Infectious protozoa include, but are not limited to, Plasmodium spp., 20 e.g., Plasmodiumfalciparum; Trypanosomes, e.g., Trypanosoma cruzi; and Toxoplasma gondii. [0133] Allergens include, but are not limited to, pollens, insect venoms, animal dander dust, fungal spores and drugs (e.g., penicillin). Examples of natural, animal and plant allergens include proteins specific to the following genera: Canine 25 (Canis familiaris); Dermatophagoides (e.g., Dermatophagoidesfarinae); Felis (Felis domesticus); Ambrosia (Ambrosia artemiisfolia; Lolium (e.g., Lolium perenne or Lolium multiflorum); Cryptomeria (Cryptomeria japonica); Alternaria (Alternaria alternata); Alder; Alnus (Alnus gultinosa); Betula (Betula verrucosa); Quercus (Quercus alba); Olea (Olea europa); Artemisia (Artemisia vulgaris); Plantago (e.g., 30 Plantago lanceolata); Parietaria (e.g., Parietaria officinalis or Parietaria judaica); Blattella (e.g., Blattella germanica); Apis (e.g., Apis multiflorum); Cupressus (e.g., Cupressus sempervirens, Cupressus arizonica and Cupressus macrocarpa); Juniperus - 39 - (e.g., Juniperus sabinoides, Juniperus virginiana, Juniperus communis and Juniperus ashei); Thuya (e.g., Thuya orientalis); Chamaecyparis (e.g., Charnaecyparis obtusa); Periplaneta (e.g., Periplaneta americana); Agropyron(e.g., Agropyron repens); Secale (e.g., Secale cereale); Triticum (e.g., Triticum aestivum); Dactylis (e.g., Dactylis 5 glomerata); Festuca (e.g., Festuca elatior); Poa (e.g., Poa pratensis or Poa compressa); Avena (e.g., Avena sativa); Holcus (e.g., Holcus lanatus); Anthoxanthum (e.g., Anthoxanthum odoratum); Arrhenatherum (e.g., Arrhenatherum elatius); Agrostis(e.g., Agrostis alba); Phleum (e.g., Phleum pratense); Phalaris (e.g., Phalaris arundinacea); Paspalum (e.g., Paspalum notatum); Sorghum (e.g., Sorghum halepensis); and Bromus 10 (e.g., Bromus inermis). [0134] Any of a variety of known cancer- or tumor-associated antigens can be inserted into a HDV of the invention. The entire antigens may be, but need not be, inserted. Instead, a portion of a cancer- or tumor-associated antigen, e.g., an epitope, particularly an epitope that is recognized by a CTL, may be inserted. Tumor-associated 15 antigens (or epitope-containing fragments thereof) which may be inserted into HDV include, but are not limited to, MAGE-2, MAGE-3, MUC-1, MUC-2, HER-2, high molecular weight melanoma-associated antigen MAA, GD2, carcinoembryonic antigen (CEA), TAG-72, ovarian-associated antigens OV-TL3 and MOV 18, TUAN, alpha-feto protein (AFP), OFP, CA-125, CA-50, CA-19-9, renal tumor-associated antigen G250, 20 EGP-40 (also known as EpCAM), S100 (malignant melanoma-associated antigen), p53, prostate tumor-associated antigens (e.g., PSA and PSMA), and p2lras. [0135] Other antigens of interest include, but are not limited to, sperm associated antigens, venoms, hormones, and the like. Sperm-associated proteins are known in the art, and a nucleic acid molecule encoding any such protein is suitable for 25 use herein. See, e.g., Primakoff (1994) Reproductive Immunol. 31:208-210; Naz et al. (1995) Human Reprod. Update 1:1-18; Kerretal. (1998) J. Reprod. Immunol. 40:103 118; and U.S. Pat. No. 6,197,940. Hormones of interest include, but are not limited to, human chorionic gonadotrophin (hCG). Hormones such as hCG are useful to elicit specific antibodies, for use as contraceptive. Venoms of interest include those from any 30 poisonous animal, e.g., snake venoms, including, but not limited to, a-neurotoxins, kappa toxins, p-neurotoxins, dendrotoxins, cardiotoxins, myotoxins, and hemorrhaging. Of particular interest in some embodiments are modified venoms that elicit specific antibodies, but are not themselves toxic. Such modified venoms are useful to elicit an - 40 immune response to a venom, and in many embodiments, elicit a protective immune response such that, upon subsequent exposure to the venom from an animal source, any adverse physiological effects of the venom are mitigated. [0136] A "therapeutic protein" includes a protein that the host does not 5 produce but is in need of; a protein that the host does not normally produce, but which has a therapeutic activity; a protein that the host produces, but produces in inadequate amounts; a protein that the host produces but in a form which is inactive, or which has reduced activity compared with an activity normally associated with the protein; or a protein that the host produces in adequate amounts and with normal activity associated 10 with that protein. Therapeutic proteins include naturally-occurring proteins, and recombinant proteins whose amino acid sequences differ from a naturally-occurring counterpart protein, which recombinant proteins have substantially the same, an altered activity, or enhanced activity relative to a naturally-occurring protein. Proteins that have therapeutic activity include, but are not limited to, cytokines, including, but not limited 15 to, interleukins, endothelin, colony stimulating factors, tumor necrosis factor, and interferons; hormones, including, but not limited to, a growth hormone, insulin; growth factors, including, but not limited to human growth factor, insulin-like growth factor; bioactive peptides; trophins; neurotrophins; soluble forms of a membrane protein including, but not limited to, soluble CD4; enzymes; regulatory proteins; structural 20 proteins; clotting factors, including, but not limited to, factor XIII; erythropoietin; tissue plasminogen activator; etc. [0137] In specific embodiments, the exogenous polypeptide is a cytokine, which according to the present invention also encompasses a chemokine. In certain embodiments, the cytokine is identical or substantially identical to a cytokine produced 25 in a subject to which the recombinant virus is administered. [0138] Although no particular limitation exists regarding the particular cytokine encoded by the HSI, the cytokine is suitably one that is associated with antiviral immune responses in the host organism. Non-limiting examples of suitable cytokines include interleukins, interferons, tumor necrosis factor-alpha (TNF-a), alpha 30 defensins, RANTES (CCL5), CXCL1O (IP1O) and the like. [0139] The HSI may comprise a plurality of cytokine-encoding nucleic acid sequences. This includes duplicate(s) of a nucleic acid sequence encoding a specific - 41 cytokine and/or combinations of different nucleic acid sequences encoding different cytokines. [0140] In specific embodiments, the cytokine expressed by the recombinant virus may be sufficient to reduce the virulence (i.e., degree of pathogenicity) of the 5 virus such that potentially adverse effects are avoided in a subject to which the virus is administered. The virulence of a recombinant virus of the present invention may be assessed using a number of methods known in the art. For example, the virulence of a given recombinant virus may be assessed using cell culture-based assays, animal models (e.g., mouse, rat, hamster, primate) and/or assessing the monitoring subjects(s) 10 to which the virus has been administered. [0141] In certain embodiments the cytokine is an interferon. In illustrative embodiments of this type, the interferon is a type I interferon. For example, the interferon may be a mammalian type I interferon (e.g., interferon-alpha (IFN-a), interferon-beta (IFN-), interferon-kappa (IFN-K), interferon-delta (IFN-6), interferon 15 epsilon (IFN-s), interferon-tau (IFN-T), interferon-omega (IFN-w), or interferon-zeta (IFN-()). Alternatively, the interferon may be a type II interferon (e.g., interferon gamma (IFN-y)) or a type III interferon (e.g., an IFN-A such IFN-Al, IFN-A2 and IFN A3). The use of interferons with the recombinant HDVs of the present invention is particularly advantageous as interferons interfere with viral replication within host cells, 20 activate immune cells, such as natural killer cells and macrophages; increase recognition of infection or tumor cells by up-regulating antigen presentation to T lymphocytes; and increase the ability of uninfected host cells to resist new infection by virus. Thus, interferon-expressing HDVs are useful in a range of applications including the treatment of viral infections (e.g., HBV infections, HBV/HDV co-infections or HCV infections). 25 [0142] In certain embodiments the cytokine is interferon-beta (IFN-). Suitably, the cytokine is mammalian interferon-beta (IFN-), and more suitably human interferon-beta (IFN-). Without limitation to a specific sequence, the human interferon-beta (IFN-) may be defined by the amino acid sequence set forth in GenBank accession number AAC41702.1. 30 [0143] The HSI encoding the exogenous protein to be produced by a host cell following infection of the host cell by a recombinant HDV of the present invention can be obtained by techniques known in the art, including but not limited to, chemical or - 42 enzymatic synthesis, purification from genomic DNA of the microorganism, by purification or isolation from a cDNA encoding the exogenous protein, by cDNA synthesis from RNA of an organism, or by standard recombinant methods (Sambrook et al., (1989) "Molecular Cloning: A Laboratory Manual", (2nd ed., Cold Spring Harbor 5 Laboratory Press, Plainview, New York; and Ausubel et al. (Eds), (2000-2010), "Current Protocols in Molecular Biology", John Wiley and Sons, Inc.). Nucleotide sequences encoding many of the above-listed exogenous proteins are publicly available. Variant of such sequences can readily be generated by those skilled in the art using standard recombinant methods, including site-directed and random mutagenesis. The 10 nucleic acid molecule encoding the exogenous polypeptide can further include sequences that direct secretion of the protein from the cell, sequences that alter RNA and/or protein stability, and the like. 2.3 Ancillary elements [0144] A coding sequence of the HSI may comprise at least one nucleotide 15 sequence encoding a proteolytic cleavage site. The proteolytic cleavage site may be advantageous in facilitating cleavage and release of the encoded polypeptide from the HDAg. In certain embodiments, the proteolytic cleavage site is a so-called "self cleaving" peptide sequence. Illustrative self-cleaving peptides are encoded by some picornaviruses as well as a number of other single- and double-stranded RNA viruses 20 (Doronina et al., 2008, Biochem Soc Trans. 36:712-716; de Felipe 2004, Genet Vaccines Ther. 2:13; Halpin et al., 1999, Genet Vaccines Ther. 2:13). In some embodiments, self-cleaving peptides are selected from "2A" and "2A-like" self-cleaving sequences, which suitably comprise the consensus motif D-V/I-E-X-N-P-G-P. These sequences are understood to act co-translationally by preventing the formation of a 25 normal peptide bond between the glycine and last proline, resulting in the ribosome skipping to the next codon, and the nascent peptide cleaving between the glycine and proline. After cleavage, the short 2A or 2A-like peptide remains fused to the C-terminus of the upstream protein, while the proline is added to the N-terminus of the downstream protein. Other sequences encoding proteolytic cleavage sites and methods for their 30 incorporation into polypeptides of interest are well known in the art and described in standard texts. In some embodiments, the proteolytic cleavage site-encoding sequence is placed upstream (i.e., 5') of the HSI coding sequence. In other embodiments, the nucleotide sequence encoding the proteolytic cleavage site is located upstream (i.e., 5') - 43 and downstream (i.e., 3') of the HIS coding sequence. In still other embodiments, the proteolytic cleavage site-encoding sequence is placed upstream (i.e., 3') of the HSI coding sequence. Suitably, the proteolytic cleavage sites is positioned to facilitate release of the encoded exogenous polypeptide upon proteolytic processing of a 5 recombinant viral polyprotein precursor comprising the encoded exogenous polypeptide. [0145] In some embodiments, a coding sequence of the HSI comprises a nucleotide sequence encoding a signal peptide for directing transport of an exogenous polypeptide within a host cell (e.g., to the endoplasmic reticulum) and/or to the cell 10 exterior. [0146] In some embodiments, a coding sequence of the HSI is operably linked to an internal ribosome binding site (IRES). Any of a variety of naturally occurring or synthetic (e.g., recombinant) IRES sequences can be used in the recombinant HDV of the invention. Naturally occurring IRES sequences are known in 15 the art and include, but are not limited to, IRES sequences derived from mengovirus, bovine viral diarrhea virus (BVDV), encephalomyocarditis virus (EMCV), hepatitis C virus (HCV; e.g., nucleotides 1202-1812 of the nucleotide sequence provided under GenBank Accession number AJ242654), GTX, Cyr61 a, Cyr6lb, poliovirus, the immunoglobulin heavy-chain-binding protein (BiP), immunoglobulin heavy chain, a 20 picomavirus, murine encephalomyocarditis virus, poliovirus, and foot and mouth disease virus (e.g., nucleotide numbers 600-1058 of the nucleotide sequence provided under GenBank Accession No. AF308157). Other IRES sequences such as those reported in WO 96/01324; WO 98/49334; WO 00/44896; and U.S. Pat. No. 6,171,821 can be used in the recombinant HDVs of the invention. 25 [0147] Mutants, variants and derivatives of naturally occurring IRES sequences may be employed in the present invention provided they retain the ability to initiate translation of an operably linked coding sequence located 3' of the IRES. An IRES sequence suitable for use in the present invention has at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 30 95%, or more, nucleotide sequence identity with a naturally occurring IRES. An IRES sequence suitable for use in the present invention may also be a fragment of a naturally - 44 occurring IRES, provided the fragment functions to allow ribosome attachment and initiate translation of an operably linked Y coding region. 2.4 Illustrative size and positioning of the heterologous nucleic acid sequence [0148] Without imposing any specific limitation on the length of an 5 heterologous nucleotide sequence introduced into a parent HDV genome, in some embodiments an heterologous nucleotide sequence is from about 12 to about 3000 nucleotides in length, for example from 12 to about 18, from about 15 to about 24, from about 21 to about 30, from about 30 to about 60, from about 60 to about 90, from about 90 to about 120, from about 120 to about 150, from about 150 to about 180, from about 10 180 to about 240, from about 240 to about 300, from about 300 to about 600, from about 600 to about 1200, from about 1200 to about 1500, from about 1500 to about 2100, from about 2100 to about 2400, or from about 2400 to about 3000 nucleotides in length. In some embodiments, an heterologous nucleotide sequence is no more than 300,400,500,600,700,800,900,1000,1100,1200,1300,1400,1500,1600,1700, 15 1800, 1900,2000,2100,2200,2300,2400,2500,2600,2700,2800,2900,3000 nucleotides in length. In some embodiments, the first and second heterologous nucleotides sequences combined are no more than 150, 200, 300, 400, 500, 600, 700, 800,900,1000,1100,1200,1300,1400,1500,1600,1700,1800,1900,2000,2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000 nucleotides in length. 20 [0149] Suitably an exogenous polypeptide encoded by an HSI is from about 4 to about 1000 amino acids in length, for example from about 4 to about 6, from about 5 to about 8, from about 7 to about 10, from about 10 to about 20, from about 20 to about 30, from about 30 to about 40, from about 40 to about 50, from about 50 to about 60, from about 60 to about 80, from about 80 to about 100, from about 100 to about 200, 25 from about 200 to about 400, from about 400 to about 500, from about 500 to about 700, from about 700 to about 800, or from about 800 to about 1000 amino acids in length. In some embodiments, an exogenous polypeptide is no more than 50, 100, 150, 300, 400, 500, 600, 700, 800, 900, 1000 amino acids in length. 2.5 Preparation of nucleic acid molecules corresponding to the recombinant HDV 30 RNA genome and recombinant HDV [0150] The present invention also encompasses processes for preparing a recombinant HDV RNA genome of the invention. Illustrative process include - 45 constructing antigenomic cDNA corresponding to the recombinant HDV RNA antigenome and transcribing the cDNA to form a mixture containing an antigenomic RNA; and thereafter isolating the antigenomic RNA. These processes are well known to persons of skill in the art and include standard recombinant methods as described for 5 example by Sambrook et al., (1989) supra; and Ausubel et al. (Eds), (2000-2010), supra. [0151] The present invention is also directed toward a recombinant HDV comprising a recombinant antigenomic RNA that comprises heterologous nucleotide sequences as described herein. In an illustrative process, the recombinant HDV can be 10 produced by: [0152] (i) providing a cell (e.g., a hepatocyte such as a differentiated hepatocyte) or cell line (e.g., HepG2.2.15) that is infected with HBV or that expresses (e.g., using helper vectors) coding sequences for HBV envelope proteins or envelope proteins from a related virus (e.g., woodchuck hepatitis virus (WHV)); 15 [0153] (ii) transfecting the cells with a vector comprising a cDNA encoding the antigenomic RNA or antigenomic RNA that has been prepared for example by in vitro transcription; and [0154] (iii) isolating recombinant HDV from a supernatant of the medium of step (ii) to obtain the recombinant HDV. 20 [0155] Thus, within the scope of the present invention are a cDNA comprising a nucleotide sequence corresponding to a recombinant antigenomic HDV RNA, a cell containing the cDNA, a vector comprising the cDNA, a cell containing the cDNA, a cell containing the recombinant antigenomic RNA, and a recombinant HDV containing the recombinant RNA genome of the invention or antigenome thereof. In 25 some embodiments, the recombinant HDV containing the recombinant RNA genome of the invention or antigenome thereof is in isolated form or is substantially purified. - 46 - 3. Compositions [0156] The present invention further provides compositions, including pharmaceutical compositions, comprising a recombinant HDV of the invention. Representative compositions may include a buffer, which is selected according to the 5 desired use of the recombinant HDV, and may also include other substances appropriate to the intended use. Where the intended use is to induce an immune response, the composition is referred to as an "immunogenic" or "immunomodulating" composition. Such compositions include preventative compositions (i.e., compositions administered for the purpose of preventing a condition such as an infection) and therapeutic 10 compositions (i.e., compositions administered for the purpose of treating conditions such as an infection). An immunomodulating composition of the present invention may therefore be administered to a recipient for prophylactic, ameliorative, palliative, or therapeutic purposes. [0157] Those skilled in the art can readily select an appropriate buffer, a wide 15 variety of which are known in the art, suitable for an intended use. In some instances, the composition can comprise a pharmaceutically acceptable excipient, a variety of which are known in the art and need not be discussed in detail herein. Pharmaceutically acceptable excipients have been amply described in a variety of publications, including, for example, A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy", 20 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) H. C. Ansel et al., eds 7.sup.th ed., Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) A. H. Kibbe et al., eds., 3.sup.rd ed. Amer. Pharmaceutical Assoc. [0158] In some embodiments, the compositions comprise more than one (i.e., 25 different) recombinant HDV of the invention (e.g., recombinant HDV comprising different heterologous nucleic acid sequences including different HSIs). [0159] Pharmaceutical compositions of the present invention may be in a form suitable for administration by injection, in a formulation suitable for oral ingestion (such as, for example, capsules, tablets, caplets, elixirs), in the form of an ointment, 30 cream or lotion suitable for topical administration, in a form suitable for delivery as an eye drop, in an aerosol form suitable for administration by inhalation, such as by - 47 intranasal inhalation or oral inhalation, or in a form suitable for parenteral administration, that is, subcutaneous, intramuscular or intravenous injection. [0160] Supplementary active ingredients such as adjuvants or biological response modifiers can also be incorporated into pharmaceutical compositions of the 5 present invention. Although adjuvant(s) may be included in pharmaceutical compositions of the present invention they need not necessarily comprise an adjuvant. In such cases, reactogenicity problems arising from the use of adjuvants may be avoided. [0161] In general, adjuvant activity in the context of a pharmaceutical 10 composition of the present invention includes, but is not limited to, an ability to enhance the immune response (quantitatively or qualitatively) induced by immunogenic components in the composition (e.g., a recombinant virus of the present invention). This may reduce the dose or level of the immunogenic components required to produce an immune response and/or reduce the number or the frequency of immunizations required 15 to produce the desired immune response. [0162] Any suitable adjuvant may be included in a pharmaceutical composition of the present invention. For example, an aluminum-based adjuvant may be utilized. Suitable aluminum-based adjuvants include, but are not limited to, aluminum hydroxide, aluminum phosphate and combinations thereof. Other specific examples of 20 aluminum-based adjuvants that may be utilized are described in European Patent No. 1216053 and United States Patent No. 6,372,223. Other suitable adjuvants include Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.); AS-2 (SmithKline Beecham, Philadelphia, Pa.); aluminum salts such as aluminum hydroxide 25 gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A; oil in water emulsions including those described in European Patent No. 0399843, United States Patent No. 7,029,678 and PCT Publication No. WO 30 2007/006939; and/or additional cytokines, such as GM-CSF or interleukin-2, -7, or -12, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF) monophosphoryl lipid A (MPL), cholera toxin (CT) or its constituent subunit, - 48 heat labile enterotoxin (LT) or its constituent subunit, toll-like receptor ligand adjuvants such as lipopolysaccharide (LPS) and derivatives thereof (e.g., monophosphoryl lipid A and 3-Deacylated monophosphoryl lipid A), muramyl dipeptide (MDP) and F protein of respiratory syncytial virus (RSV). 5 [0163] Pharmaceutical compositions of the present invention may be provided in a kit. The kit may comprise additional components to assist in performing the methods of the present invention such as, for example, administration device(s), buffer(s), and/or diluent(s). The kits may include containers for housing the various components and instructions for using the kit components in the methods of the present 10 invention. 4. Dosages and Routes of Administration [0164] The recombinant HDV composition is administered in an "effective amount" that is, an amount effective to achieve production of the exogenous polypeptide in the host at a desired level. One skilled in the art would be able, by 15 routine experimentation, to determine an effective, non-toxic amount of a recombinant virus described herein to include in a pharmaceutical composition of the present invention for the desired therapeutic outcome. In general, a pharmaceutical composition of the present invention can be administered in a manner compatible with the route of administration and physical characteristics of the recipient (including health status) and 20 in such a way that it elicits the desired effect(s) (i.e. therapeutically effective, immunogenic and/or protective). For example, the appropriate dosage of a pharmaceutical composition of the present invention may depend on a variety of factors including, but not limited to, a subject's physical characteristics (e.g., age, weight, sex), whether the compound is being used as single agent or adjuvant therapy, the type of 25 MHC restriction of the patient, the progression (i.e., pathological state) of a virus infection, and other factors that may be recognized by one skilled in the art. Various general considerations that may be considered when determining an appropriate dosage of a pharmaceutical composition of the present invention are described, for example, in Gennaro (2000) "Remington: The Science and Practice of Pharmacy", 20th edition, 30 Lippincott, Williams, & Wilkins; and Gilman et al., (Eds), (1990), "Goodman And Gilman's: The Pharmacological Bases of Therapeutics", Pergamon Press. - 49 - [0165] The dose of recombinant HDV administered to an individual will generally be in a range of from about 102 to about 108, from about 103 to about 106, or from about 104 to about 10 5 genome equivalents (GE). [0166] In some embodiments, an "effective amount" of a subject recombinant 5 HDV is an amount sufficient to achieve a desired therapeutic effect. [0167] In some embodiments, an "effective amount" of a subject recombinant HDV is an amount of recombinant HDV that is effective in a selected route of administration to elicit an immune response to an exogenous polypeptide. [0168] In some embodiments, e.g., where the exogenous polypeptide is one 10 associated with a pathogenic microorganism, an "effective amount" is an amount that is effective to facilitate protection of the host against infection, or symptoms associated with infection, by a pathogenic organism, e.g., to reduce a symptom associated with infection, and/or to reduce the number of infectious agents in the individual. In these embodiments, an effective amount reduces a symptom associated with infection and/or 15 reduces the number of infectious agents in an individual by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%, or more, when compared to the symptom or number of infectious agents in an individual not treated with the recombinant HDV, or treated with the parent HDV. Symptoms of infection by 20 a pathogenic microorganism, as well as methods for measuring such symptoms, are known in the art. Methods for measuring the number of pathogenic microorganisms in an individual are standard in the art. [0169] In some embodiments, e.g., where the exogenous polypeptide is a cancer- or tumor-associated antigen, an "effective amount" of a recombinant HDV is an 25 amount of recombinant HDV that is effective in a route of administration to elicit an immune response effective to reduce or inhibit cancer or tumor cell growth, to reduce cancer or tumor cell mass or cancer or tumor cell numbers, or to reduce the likelihood that a cancer or tumor will form. In these embodiments, an effective amount reduces tumor growth and/or the number of tumor cells in an individual by at least about 10%, 30 at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%, or more, when compared to the tumor growth and/or number of tumor cells in an individual not treated - 50 with the recombinant HDV or treated with the parent HDV. Methods of measuring tumor growth and numbers of tumor cells are known in the art. [0170] The amount of recombinant HDV in each dose is selected as an amount that induces an immune response to the encoded exogenous polypeptide 5 antigen, and/or that induces an immunoprotective or other immunotherapeutic response without significant, adverse side effects generally associated with typical vaccines. Such amount will vary depending upon which specific exogenous polypeptide is employed, whether or not the vaccine formulation comprises an adjuvant, and a variety of host dependent factors. 10 [0171] An effective dose of recombinant HDV nucleic acid-based composition will generally involve administration of from about 1-1000 pg of nucleic acid. Alternatively, an effective dose of recombinant HDV will generally be in a range of from about 102 to about 108, from about 103 to about 106, or from about 104 to about 10 5 genome equivalents (GE). An optimal amount for a particular immunomodulating 15 composition can be ascertained by standard studies involving observation of antibody titers and other responses in subjects. The levels of immunity provided by the immunomodulating composition can be monitored to determine the need, if any, for boosters. Following an assessment of antibody titers in the serum, optional booster immunizations may be desired. The immune response to the protein of this invention is 20 enhanced by the use of adjuvant and/or an immunostimulant. [0172] A pharmaceutical composition of the present invention can be administered to a recipient by standard routes, including, but not limited to, parenteral (e.g., intravenous). [0173] A pharmaceutical composition of the present invention may be 25 administered to a recipient in isolation or in conjunction with additional therapeutic agent(s). In embodiments where a pharmaceutical composition is concurrently administered with therapeutic agent(s), the administration may be simultaneous or sequential (i.e., pharmaceutical composition administration followed by administration of the agent(s) or vice versa). 30 [0174] Typically, in treatment applications, the treatment may be for the duration of the disease state or condition. Further, it will be apparent to one of ordinary skill in the art that the optimal quantity and spacing of individual dosages will be -51 determined by the nature and extent of the disease state or condition being treated, the form, route and site of administration, and the nature of the particular individual being treated. Optimum conditions can be determined using conventional techniques. [0175] In many instances (e.g., preventative applications), it may be desirable 5 to have several or multiple administrations of a pharmaceutical composition of the present invention. For example, a pharmaceutical composition may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times. The administrations may be from about one to about twelve week intervals, and in certain embodiments from about one to about four week intervals. Periodic re-administration may be desirable in the case of recufrent 10 exposure to a particular pathogen or allergen targeted by a pharmaceutical composition of the present invention. [0176] It will also be apparent to one of ordinary skill in the art that the optimal course of administration can be ascertained using conventional course of treatment determination tests. 15 [0177] Where two or more entities are administered to a subject "in conjunction" or "concurrently" they may be administered in a single composition at the same time, or in separate compositions at the same time, or in separate compositions separated in time. [0178] Certain embodiments of the present invention involve the 20 administration of pharmaceutical compositions in multiple separate doses. Accordingly, the methods for the prevention (i.e. vaccination) and treatment of infection described herein encompass the administration of multiple separated doses to a subject, for example, over a defined period of time. Accordingly, the methods for the prevention (i.e., vaccination) and treatment of infection disclosed herein include administering a 25 priming dose of a pharmaceutical composition of the present invention. The priming dose may be followed by a booster dose. The booster may be for the purpose of re vaccination. In various embodiments, the pharmaceutical composition or vaccine is administered at least once, twice, three times or more. [0179] Methods for measuring the immune response are known to persons of 30 ordinary skill in the art. Exemplary methods include solid-phase heterogeneous assays (e.g., enzyme-linked immunosorbent assay), solution phase assays (e.g., electrochemiluminescence assay), amplified luminescent proximity homogeneous - 52 assays, flow cytometry, intracellular cytokine staining, functional T-cell assays, functional B-cell assays, functional monocyte-macrophage assays, dendritic and reticular endothelial cell assays, measurement of NK cell responses, IFN-y production by immune cells, quantification of virus RNA/DNA in tissues or biological fluids (e.g., 5 quantification of HBV RNA (GE) in serum, or quantification of HBV cccDNA in the liver), oxidative burst assays, cytotoxic-specific cell lysis assays, pentamer binding assays, and phagocytosis and apoptosis evaluation. 5. Uses of Recombinant Hepatitis Delta Viruses of the Invention [0180] Recombinant HDVs of the invention are useful to deliver a 10 polypeptide to a mammalian host (e.g., in the liver of the host); and to elicit or increase an immune response to an antigen encoded by the recombinant virus. Recombinant HDVs of the present are also useful for producing the exogenous polypeptide in host cells, such as mammalian, particularly human, cells or other cell types. The exogenous protein can further be isolated or purified using standard methods. 15 5.1 Methods for delivering a therapeutic polypeptide to a mammalian host [0181] The present invention provides methods for delivering a polypeptide to a mammalian host. The methods generally involve administering a recombinant HDV of the invention to a vertebrate host, wherein the virus enters a host cell and the exogenous polypeptide is expressed either by itself or as a polyprotein with HDAg, 20 which is optionally processed in a host cell to provide separate polypeptides. In some embodiments, the exogenous polypeptide remains intracellular. In other embodiments, the exogenous polypeptide becomes associated with the plasma membrane of a host cell. In other embodiments, the exogenous polypeptide is secreted from the cell. In those embodiments in which the exogenous polypeptide is secreted from the cell, the 25 exogenous polypeptide can be secreted into the extracellular milieu, e.g., the interstitial fluid; and/or the exogenous polypeptide can enter the blood stream; and/or the exogenous polypeptide can bind to and/or enter a cell other than the cell in which it was produced. [0182] In some embodiments, the exogenous polypeptide is one that has 30 therapeutic activity, such that when the protein is produced in the mammalian host, a therapeutic effect is achieved. Whether, and at what level, a therapeutic protein is produced in an individual is readily determined using any known method, e.g., methods - 53 for detecting the presence of and/or measuring the amount of a protein, including, but not limited to, an enzyme-linked immunosorbent assay, a radioimmunoassay, and the like, using specific antibody; and methods for detecting the presence of and/or measuring the amount of a biological activity associated with the protein. Whether a 5 therapeutic effect is achieved can be determined using a method appropriate to the particular therapeutic effect. For example, whether a therapeutic effect is achieved when insulin is delivered to a host using the subject method can be determined by measuring glucose levels in the individual. 5.2 Methods of increasing an immune response to an exogenous polypeptide 10 [0183] The present invention provides methods for eliciting an immune response to an antigen. The methods generally involve administering a recombinant HDV of the invention to a vertebrate host, wherein the virus enters a host cell, the exogenous polypeptide is expressed as a polyprotein with at least one virus protein, and an immune response is elicited to the exogenous polypeptide. 15 [0184] In some embodiments, recombinant HDVs as described herein are useful for inducing an immune response to an antigen in an individual. When the exogenous polypeptide is produced in a vertebrate host, it induces an immune response to the exogenous polypeptide. In many embodiments, the immune response protects against a condition or disorder caused by or associated with expression of or the 20 presence in the host of, an antigen comprising the epitope. In some embodiments the antigen is a pathogen-associated antigen, and the immune response provides protection against challenge or infection by the exogenous pathogen (bacterial, viral, fungal, parasitic) in which the antigen occurs. Recombinant HDV of the invention are, therefore, useful as immunomodulating compositions (also referred to herein as 25 "immunogenic compositions") to elicit and/or enhance an immune response to the antigen. [0185] In some embodiments, the exogenous polypeptide is an antigenic polypeptide of a microbial pathogen. Such recombinant HDVs can then be administered to a host to prevent or treat infection by the pathogen, or to prevent or treat symptoms of 30 such pathogenic infection. Of particular interest in some embodiments is the prevention or treatment of infection or disease caused by microbial pathogens that, during the course of infection, are present intracellularly, e.g., viruses (e.g., HIV), bacteria (e.g., - 54 - Shigella, Listeria, mycobacteria, and the like), parasites (e.g., malarial parasites, illustrative examples of which include Plasmodiumfalciparum; trypanosomes, and the like), etc. Antigenic polypeptides of such microbial pathogens are well known in the art, and can be readily selected for use in the present recombinant HDV immunomodulating 5 composition by the ordinarily skilled artisan. [0186] In addition, a recombinant HDV of the invention can be used as a delivery vehicle to delivery any antigen to an individual, to provoke an immune response to the antigen. In some embodiments, recombinant HDV of the invention are used as bivalent or multivalent immunomodulating composition to treat human or 10 veterinary diseases caused by infectious pathogens, particularly viruses, bacteria, and parasites. Examples of epitopes which could be delivered to a host in a multivalent HDV composition of the invention include multiple epitopes from various serotypes of Group B streptococcus, influenza virus, rotavirus, and other pathogenic organisms known to exist in nature in multiple forms or serotypes; epitopes from two or more 15 different pathogenic organisms; and the like. [0187] Suitable subjects include naive subjects (i.e., subjects who were never exposed to the antigen such that the antigen or pathogen entered the body), and subjects who were previously exposed to the antigen, but did not mount a sufficient immune response to the pathogenic organism. 20 [0188] In other embodiments, a polypeptide antigen expressed on a given cancer or tumor cell (e.g., a cancer- or tumor-associated antigen) is inserted into a recombinant HDV of the invention as described herein. Such recombinant HDV can be administered to an individual having, or suspected of having, a cancer or tumor. In some cases, such recombinant HDV can be administered to an individual who does not have a 25 cancer or tumor, but in whom protective immunity is desired. As is often the case, the immune system does not mount an immune response effective to inhibit or suppress cancer or tumor growth, or eliminate a cancer or tumor altogether. Cancer- or tumor associated antigens are often poorly immunogenic; perhaps due to an active and ongoing immunosuppression against them. Furthermore, cancer patients tend to be 30 immunosuppressed, and only respond to certain T-dependent antigens. In these cases, introduction into the host of a recombinant HDV of the invention which expresses an - 55 exogenous peptide polypeptide corresponding to an antigen expressed on the tumor cell surface can elicit an immune response to the tumor in the host. [0189] Non-limiting cancer- or tumor-associated antigens (or epitope containing fragments thereof) which may be inserted into HDV include, but are not 5 limited to, MAGE-2, MAGE-3, MUC-1, MUC-2, HER-2, high molecular weight melanoma-associated antigen MAA, GD2, carcinoembryonic antigen (CEA), TAG-72, ovarian-associated antigens OV-TL3 and MOV18, TUAN, alpha-feto protein (AFP), OFP, CA-125, CA-50, CA-19-9, renal tumor-associated antigen G250, EGP-40 (also known as EpCAM), S100 (malignant melanoma-associated antigen), p53, prostate 10 tumor-associated antigens (e.g., PSA and PSMA) and p2lras. [0190] Suitable subjects include subjects who do not have cancer, but are considered at risk of developing cancer; and subjects who have cancer, but who have not mounted an immune response sufficient to reduce or eliminate the cancer. [0191] Whether an immune response has been elicited to a pathogenic 15 organism, cancer or tumor can be determined (quantitatively, e.g., by measuring a parameter, or qualitatively, e.g., by assessing the severity of a symptom, or by detecting the presence of a particular parameter) using known methods. Methods of measuring an immune response are well known in the art and include enzyme-linked immunosorbent assay (ELISA) for detecting and/or measuring antibody specific to a given pathogenic 20 organism, cancer or tumor antigen; and in vitro assays to measure a cellular immune response (e.g., a CTL assay using labeled, inactivated cells expressing the epitope on their cell surface with MHC Class I molecules). Whether an immune response is effective to facilitate protection of the host against infection, or symptoms associated with infection, by a pathogenic organism can be readily determined by those skilled in 25 the art using standard assays, e.g., determining the number of pathogenic organisms in a host (e.g., measuring viral load, and the like); measuring a symptom caused by the presence of the pathogenic organism in the host (e.g., body temperature, CD4' T cell counts, and the like). Whether an immune response is elicited to a given cancer or tumor can be determined by methods standard in the art, including, but not limited to, assaying 30 for the presence and/or amount of cancer- or tumor-associated antigen-specific antibody in a biological sample derived from the individual, e.g., by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and the like; assaying for the - 56 presence and/or numbers of CTLs specific for a cancer- or tumor-associated antigen; and the like. Assays for determining the presence and/or numbers of cancer- or tumor associated antigen-specific CTLs are known in the art and include, but are not limited to, chromium-release assays, tritiated thymidine incorporation assays, and the like. 5 Standard immunological protocols may be used, which can be found in a variety of texts, including, e.g., Current Protocols in Immunology (J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach and W. Strober Eds. 1991). Whether an immune response is effective in reducing the number of tumor cells in an individual can be determined by standard assays, including, but not limited to, measuring tumor cell mass, 10 measuring numbers of tumor cells in an individual, and measuring tumor cell metastasis. Such assays are well known in the art and need not be described in detail herein. 5.3 Methods for producing an exogenous polypeptide [0192] The invention further provides methods of producing an exogenous 15 polypeptide in a vertebrate host cell. The methods generally involve contacting a susceptible host cell with a recombinant HDV of the invention with, culturing the host cell for a period of time to allow production of the exogenous polypeptide by the host cell. In some embodiments, the methods further comprise purifying the exogenous polypeptide from the host cell or from the culture medium. 20 [0193] In some embodiments, the exogenous protein remains intracellular (e.g., in the cytoplasm, in a cell membrane, or in an organelle), in which case the cells are disrupted. A variety of protocols for disrupting cells to release an intracellular protein are known in the art, and can be used to extract an exogenous protein from a cell. In other embodiments, the exogenous protein is secreted into the medium in which 25 the cells are grown. [0194] Any convenient protein purification procedures may be employed, where suitable protein purification methodologies are described in Guide to Protein Purification, (Deuthser ed.) (Academic Press, 1990). For example, a lysate may prepared from the infected host cell, or a cell culture supernatant may be produced, and 30 the exogenous protein purified using HPLC, exclusion chromatography, gel electrophoresis, affinity chromatography, and the like. - 57 - [0195] The methods disclosed herein may provide several improvements over existing methods, particularly in the context of recombinant virus stability infection. [0196] One improvement may be that an heterologous nucleotide sequence inserted in a HDV genome may remain genetically stable (i.e. resist mutation/deletion) 5 over extended numbers of viral replication cycles, provided that a substantially complementary heterologous nucleotide sequence is also inserted into the HDV genome at a different site to permit annealing between the heterologous nucleotide sequences. [0197] Another improvement may be that an exogenous cytokine expressed by a recombinant virus of the present invention (e.g., a type-I IFN such as interferon 10 beta) may attenuate virulence in a host organism to which the virus is administered. This may result in a self-limiting infection minimizing potentially adverse effects on the host organism. [0198] Another improvement may be that despite the attenuated virulence, the administration of a recombinant virus of the present invention to a subject may 15 induce a similar level of immunity against the targeted microorganism (e.g., a target virus) to that which may be achieved by administering the targeted microorganism (i.e. wild-type). [0199] A further improvement may be that an exogenous cytokine expressed by a recombinant virus of the present invention (e.g., a type I IFN such as interferon 20 beta) may act as a molecular adjuvant in the host organism enhancing humoral and/or cell-mediated immunity. [0200] Still another improvement may be that a recombinant virus of the present invention administered to a subject may continue to propagate until the immune system is sufficiently activated to halt the infection, thereby providing a means of 25 inducing stronger immune responses. [0201] Yet another improvement may be that a recombinant virus of the present invention administered to a subject may not revert to a pathogenic state over extended numbers of viral replication cycles. [0202] Another improvement may be that the expression of cytokine by the 30 recombinant virus may prevent the appearance of revertant viruses. - 58 - [0203] It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the present invention as broadly described. The present embodiments are, therefore, to be considered in all 5 respects as illustrative and not restrictive. [0204] In order that the invention may be readily understood and put into practical effect, particular preferred embodiments will now be described by way of the following non-limiting examples. - 59 - EXAMPLES EXAMPLE 1 CONSTRUCTING A RECOMBINANT HDV CAPABLE OF CO-EXPRESSING IFN-BETA [0205] Based on a well-characterized, 1.2-length cDNA clone of HDV 5 (Gudima et al. 2002, J Virol. 76(8):3709-19), a recombinant HDV was generated with a genome that is much longer than that of the wild-type virus (Figure 2). The new virus has been named rHDV-huIFNbeta-IRES-HDAg and contains a coding sequence for the human IFN-3 protein followed by the EMCV IRES, inserted downstream of the putative HDV promoter and immediately upstream of the hepatitis delta antigen 10 (HDAg) open reading frame. The inserted human IFN-3 coding sequence is based on the GenBank reference sequence NM_002176.2 but the sequence has been artificially edited to (i) increase the G/C content, i.e. 88 nucleotides in 78 codons have been edited to increase the G/C content from 45 to 60%; (ii) optimize codon usage; and (iii) destroy alter-native open reading frames. Furthermore, partially complementary, so-called 15 'stabilizing' sequences that 'mirror' the IFN coding and IRES sequence have been inserted into the genome to restore the 'rod-like' RNA secondary structure of the genome/ anti-genome that has been destroyed by the first insertion. Note that these sequences have also been artificially edited to (i) reduce complementarity (85 mismatches, 10 insertions, and 9 deletions); (ii) introduce 'Wobble' base-pairing; and 20 (iii) introduce a unique restriction site. Due to the editing of the IFN gene and any complementary sequence, the present inventors were not able to rely on 'conventional' cDNAs for the generation of recombinant HDVs; instead they employed in vitro gene synthesis to generate all inserts. [0206] The nucleotide sequence of rHDV-huIFNbeta-IRES-HDAg 25 comprises, consists or consists essentially of the sequence: [0207] cctgagccaagttccgagcgaggagacgcggggggaggatcagctcccgag aggggatgtcacggtaaagagcattggaacgtcggagaaactactcccaagaagcaaagagagg tcttaggaagcggacgagatccccacaacgccggagaatctctggaaggggaaagaggaaggtg gaagaaaaaggggcgggcctcccgatccgaggggcccaatcccagatctggagagcactccggc 30 ccgaagggttgagtagcactcagagggaggaatccactcggagatgagcagagaaatcacctcc agaggaccccttcagcgaacaagaggcgcttcgagcggtaggagtaagaccatagcgataggag gagatgctaggagtagggggagaccgaagcgaggaggaaagcaaagaaagcaacggggctagcc - 60 ggtgggtgttccgccccccgagaggggacgagtgaggcttatcccggggaactcgacttatcgt ccccatctagcgggaccccggacccccttcgaaagtgaccggagggggtgctgggaacaccggg gaccagtggagccatgggatgcccttcccgatgctcgattccgactccccccccaagggtcgcc caggaatggcgggaccccactctgcagggtccgcgttccatcctttcttacctgatggccggca 5 tggtcccagcctcctcgctggcgccggctgggcaacattccgaggggaccgtcccctcggtaat ggcgaatgggacccacaaatctctctagattccgatagagaatcgagagaaaagtggctctccc ttagccatccgagtggacgtgcgtcctccttcggatgcccaggtcggaccgcgaggaggtggag atgccatgccgacccgaagaggaaagaaggacgcgagacgcaaacctgtgagtggaaacccgct ttattcactggggtcgacaactctggggagaaaagggcggatcggctgggaagagtatatccta 10 tggaaatccctggtttcccctgatgtcagcccctccccggtccgagagaagggggactccggg actccctgcagattggggacgaagccgcccccgggcgctcccctcgatccaccttcgagggggt tcacacccccaaccggcgggccggctactcttctttcccttctctcgtcttcctcggtcaacct cctgagttcctcttcttcctccttgctgaggttcttgcctcccgccgatagctgcttcttcttg ttctcgagggccttccttcgtcggtgatcctgcctctccttgtcggtgaatcctcccctgagag 15 gcctcttcccaggtccggagtctacctccatctggtccgttgggccctcttgccgggggagc cccctctccatccttatccttctttccgagaattcctttgatgttccccagccagggattttcg tcctctatcttcttgagtttcttctttgtcttccggaggtctctctcgagttcctctaacttct ttcttccggccacccactgctcgaggatctcttctctccctccgcggttcttcctcgactcgga ccggctcatggtattatcgtgtttttcaaaggaaaaccacgtccccgtggttcggggggcctag 20 acgttttttaacctcgactaaacacatgtaaagcatgtgcaccgaggccccagatcagatccca tacaatggggtaccttctgggcatccttcagccccttgttgaatacgcttgaggagagccattt gactctttccacaactatccaactcacaacgtggcactggggttgtgccgcctttgcaggtgta tcttatacacgtggcttttggccgcagaggcacctgtcgccaggtggggggttccgctgcctgc aaagggtcgctacagacgttgtttgtcttcaagaagcttccagaggaactgcttccttcacgac 25 attcaacagaccttgcattcctttgggagaggggaaagacccctaggaatgctcgtcaagaag acagggccaggtttccgggccctcacattgccaaaagacggcaatatggtggaaaataactcag ttccggaggtaaccggtcagccggttgatgaagtagaagttccgcaggatctccacccggacga tggtccaggcgcagtgt gagtactccttggcct tcaggtagtgcaggatccgcccgtagtaccg cttcaggtgcaggctgctcatgagcttgccccgggtgaagtcctccttctccagcttctcctcc 30 aggacggtcttcaggtggttgatctggtggtagacgttggccaggaggttctccacgatggtct cgttccagccggtgctagagctgtcctgccggaagatggcgaagatgttctggagcatctcgta gatggtcagggcggcgtcctccttctggaactgctgcagctgcttgatctcctcggggatgtcg aagttcatcctgtccttgaggcagtactccagccgcccgttcagctgccacaggagcttctggc actggaagttgctgctccgctgcaggaagcccagcaggttgtagctcatggacagggcggtggt 35 ggagaagcacagcaggagggcgatctggaggaggcacttgttggtcatctcggctagaggcggc agtcctcagtactcttactcttttctgtaaagaggagactgctggactcgccgcccgagcccga gcctgaccaacacgtgccagcctccagaaggccctcctgccctgctcaccaccaccgcattgtc -61catgaggaacaacctgcagggctccgacagcggagctgcaact tccacagccagagcct cctgc ggcagcgagaacgggcggacggagtgcacgcctcaagatcaggatgcacttcgtcgtccccgtg gagatcctgcagctgctgcggcctgaaggtggacgccgccgagaccatcctacgagcagctcca gaactacttcgccatcgcaccggcaggtgagctctagcgcggctggtgcgagaccttcgtggag 5 tccctcctggcctcgtctaccaccagcacgaccacctgacgtccgtcctggcgagaagctggag ctggaggacaacacccggaaggcaagcacgtgagcccctgcaccaagagcggtactcagggcgg aatccaccactaccaccaggccaagcgagtacagcctcgcgcctggacgtacgtccgggaggag atccaagcggaacttcaccttcatcctccggctgaccggaaacctccggcactgagttactttc caccatatgccgtctggtggcaatgtgacgggcccggtcgcctggccctgcgcttcttgccggg 10 catacctaggggtcgaacccctctcgccgaaggatcgcaaggtctgcggaatgtcgtgggaag cagaccctctggaagccgcttgaagacacccaacgtctgtcggcgaccctgcgcaggggcggc tccccccagcctggcgacaggcgcctcagcggccgcgccacgtgactaagatacacctgcgctg gcggcacgcaccccagtgcccgttgtgagttggcgagttgtggctggagtcaacatggcactc ct cctgcgtatt caactcggggctgt cggatgcccagctggtaccccgcgtatgggat ctgcgc 15 tggggcctcggagcacatgcttgccatgtgttacgtcgaggttagaaaacgtcgcggccccccg ctccacgcggacgtggttcgtcctttgaattacacgataatgcc [SEQ ID NO:2]; [0208] wherein: [0209] Corrected* genomic (-) HDV sequence as set forth in SEQ ID NO: 1 is shown in black; 20 [0210] + IIFN-beta coding sequence is shown in gray italics; [0211] + IFN-beta complementary sequence is shown in gray bold italics; [0212] + EMCV IRES sequence is shown in black bold typeface; [0213] + EMCV IRES complementary sequence is shown in black shadow typeface. 25 [0214] The present inventors have extensively modeled the consequences of large insertions into the wild-type HDV genome in silico by using RNAfold, a minimum free energy RNA structure prediction program (University of Vienna, Austria; http://ma.tbi.univie.ac.at). They found that an insertion of the IFN coding sequence alone destabilizes the 'rod-like' structure of the HDV genome with structural 30 implications that reach into the putative promoter region (Figure 3b), a phenomenon that can be reversed with the introduction of partially complementary, 'stabilizing' sequences (Figure 3c). Even the introduction of the EMCV IRES, a sequences capable of forming a sophisticated RNA secondary structures on its own, did not destroy the - 62 - 'rod-like' structure of the HDV genome when a practically complementary, 'stabilizing' sequence was inserted at the opposite site of the 'rod' (Figure 3d). EXAMPLE 2 EVIDENCE FOR REPLICATION COMPETENCY OF THE NEWLY GENERATED rHDV 5 huIFNbeta-IRES-HDAg [0215] The present inventors also conducted a series of experiments in which they transfected cultured (COS) cells with eukaryotic expression plasmids encoding a 1.2-length cDNA clone of rHDVIFNbeta-IRES-HDAg and helper plasmids that provide small amounts of the HDAg in trans. Total RNA was isolated at several times post 10 transfection, cDNA was synthesized using an genomic-specific primer and then analyzed for HDV RNA by PCR using a primer pair that amplifies a product encompassing the insertion site for the IFN coding and IRES sequence. The results shown in Figure 4 indicate that rHDVIFNbeta-IRES-HDAg indeed replicates. The present inventors have repeated the experiments with different primers and analyzed 15 different time points, which has revealed that specific bands can be amplified at day 6 and day 9 but disappear later (data not shown) a finding that is in line with the intracellular replication pattern of the wild-type HDV genome. [0216] Taken together, these studies indicate that it is possible to manipulate the HDV genome in order to express a gene of interest. This newly developed 20 technology will transform HDV into a superior gene delivery vehicle for example for the liver. Furthermore a recombinant, live-attenuated HDV co-expressing IFN-3 (or other antiviral/ immune-modulatory cytokines) could be utilized as a therapeutic vaccine to treat chronic hepatitis B. EXAMPLE 3 25 ALTERNATE IRES-EMPLOYING RECOMBINANT HDV CONSTRUCT [0217] An alternative strategy for insertion and expression of heterologous nucleotide sequences in HDV is shown in Figure 5, which illustrates a schematic representation of the construct rHDV-HDAg-IRES-huIFNbeta. In this construct, an IRES sequence followed by the human IFN-3 sequence is inserted downstream of the 30 HDAg open reading frame and before the poly A signal. - 63 - [0218] The nucleotide sequence of rHDV-HDAg-IRES-huIFNbeta comprises, consists or consists essentially of the sequence: [0219] cctgagccaagttccgagcgaggagacgcggggggaggatcagctcccgag aggggatgtcacggtaaagagcattggaacgtcggagaaactactcccaagaagcaaagagagg 5 tcttaggaagcggacgagatccccacaacgccggagaatctctggaaggggaaagaggaaggtg gaagaaaaaggggcgggcctcccgatccgaggggcccaatcccagatctggagagcactccggc ccgaagggttgagtagcactcagagggaggaatccactcggagatgagcagagaaatcacctcc agaggaccccttcagcgaacaagaggcgcttcgagcggtaggagtaagaccatagcgataggag gagatgctaggagtagggggagaccgaagcgaggaggaaagcaaagaaagcaacggggctagcc 10 ggtgggtgttccgccccccgagaggggacgagtgaggcttatcccggggaactcgacttatcgt ccccatctagcgggaccccggacccccttcgaaagtgaccggagggggtgctgggaacaccggg gaccagtggagccatgggatgcccttcccgatgctcgattccgactccccccccaagggtcgcc ccatcgatcgttactttccaccatatgccgtctggtggcaatgtgacgggcccggtcgcctggc cctgcgcttcttgccgggcatacctaggggtcgaacccctctcgccgaaggatcgcaaggtctg 15 cggaatgtcgtgcggaagcagaccctctggaagccgcttgaagacacccaacgtctgtcggcga ccctgcgcaggcggcggctccccccagcctggcgacaggcgcctcagcggcccggccacgtgac taagatacacctgcgctggcggcacgcaccccagtgccccgttgtgagttggcgagttgtggct ggagtcaacatggcactcctcctgcgtattcaactcggggctgtcggatgcccagctggtaccc cgcgtatgggatctgcgctggggcctcggagcacatgcttgccatgtgttacgtcgaggttaga 20 aaacgtcgcggccccccgctccacgcggacgtggttcgtcctttgaattacacgataatgcccc tgaccaacacgtgccagcctccagaaggccctcctgccctgctcaccaccaccgcattgtccat gaggaacaacctgcagggctccgacagcggagctgcaacttccacagccagagcctcctgcggc agcgagaacgggcggacggagtgcacgcctcaagatcaggatgcacttcgtcgtccccgtggag atcctgcagctgctgcggcctgaaggtggacgccgccgagaccatcctacgagcagctccagaa 25 ctacttcgccatcgcaccggcaggtgagctctagcgcggctggtgcgagaccttcgtggagtcc ctcctggcctcgtctaccaccagcacgaccacctgacgtccgtcctggcgagaagctggagctg gaggacaacacccggaaggcaagcaggtgagcccctgcaccaagagcggtactcagggcggaat tcaccactaccaccaggccaagcgagtacagcctcgcgcctggacgtacgtccgggaggagatc caagcggaacttcaccttcatcctccggctgaccggaaacctccggcaacgatcggtggcggga 30 ccccactctgcagggtccgcgttccatcctttcttacctgatggccggcatggtcccagcctcc tcgctggcgccggctgggcaacattccgaggggaccgtcccctcggtaatggcgaatgggaccc acaaatctctctagattccgatagagaatcgagagaaaagtggctctcccttagccatccgagt ggacgtgcgtcctccttcggatgcccaggtcggaccgcgaggaggtggagatgccatgccgacc cgaagaggaaagaaggacgcgagacgcaaacctgtgagtggaaacccgctttattgatcagttc 35 cggaggtaaccggtcagccggttgatgaagtagaagttccgcaggatctccacccggacgatgg tccaggcgcagtgtgagtactccttggccttcaggtagtgcagaatccgcccgtagtaccgctt - 64 caggtgcaggctgctcatcagcttgccccgggtgaagtcctccttctccagcttctcctccagg acggtcttcaggtggttgatctggtggtagacgttggccaggaggttctccacgatggtctcgt tccagccggtgctagagctgtcctgccggaagatggcgaagatgttctggagcatctcgtagat ggtcagggcggcgtcctccttctggaactgctgcagctgcttgatctcctcggggatgtcgaag 5 ttcatcctgtccttgaggcagtactccagccgcccgttcagctgccacaggagcttctggcact ggaagttgctgctccgctgcaggaagcccagcaggttgtagctcatggacagggcggtggtgga gaagcacagcaggagggcgatctggaggaggcacttgttggtcatggtattatcgtgtttttca aaggaaaaccacgtccccgtggttcggggggcctagacgttttttaacctcgactaaacacatg taaagcatgtgcaccgaggccccagatcagatcccatacaatggggtaccttctgggcatcctt 10 cagccccttgttgaatacgcttgaggagagccatttgactctttccacaactatccaactcaca acgtggcactggggttgtgccgcctttgcaggtgtatcttatacacgtggcttttggccgcaga ggcacctgtcgccaggtggggggttccgctgcctgcaaagggtcgtacagacgttgtttgtct tcaagaagcttccagaggaactgcttccttcacgacattcaacagaccttgcattcctttggcg agaggggaaagacccctaggaatgct cgtcaagaagacagggccaggttt ccgggccctcacat 15 tgccaaaagacggcaatatggtggaaaataactgatcatgactggggtcgacaactctggggag aaaagggcggatcggctgggaagagtatatcctatggaaatccctggtttcccctgatgtccag cccctccccggtccgagagaagggggactccgggactccctgcagattggggacgaagccgccc ccgggcgctcccctcgatccaccttcgagggggttcacacccccaaccggcgggccggctactc ttctttcccttctctcgtttcctcggtcaacctcctgagttcctcttcttcctccttgctgag 20 gttcttgcctcccgccgatagctgcttcttcttgttctcgagggccttccttcgtcggtgatcc tgcctctccttgtcggtgaatcctcccctgagaggcctcttcccaggtccggagtctacctcca tctggtccgttcgggccctcttcgccgggggagccccctctccatccttatccttctttccgag aattcctttgatgttccccagccagggattttcgtcctctatcttcttgagtttcttctttgtc ttccggaggtctctctcgagttcctctaacttctttcttccggccacccactgctcgaggatct 25 cttctctccctccgcggttttcctcgactggaccggctcatctcggtagaggggcagtcc tcagtactcttactcttttctgtaaagaggagactgtggactcgccgcccgagcccgag (SEQ ID NO:3]; [0220] wherein: [0221] Corrected* genomic (-) HDV sequence as set forth in SEQ ID NO: 1 is 30 shown in black; [0222] + IFN-beta coding sequence is shown in gray bold italics; [0223] + IFN-beta complementary sequence is shown in gray italics; [0224] + EMCV IRES sequence is shown in black shadow typeface; - 65 - [0225] + EMCV IRES complementary sequence is shown in black bold typeface. EXAMPLE 4 RECOMBINANT HDV CONSTRUCT EMPLOYING SELF-CLEAVING PEPTIDE 5 [0226] An alternative strategy for insertion and expression of heterologous sequences in HDV is shown in Figure 6, which illustrates a schematic representation of the construct rHDV-HDAg-2A-huIFNbeta. In this example, the recombinant HDV genome is capable of expressing a gene of interest but that does not feature an IRES sequence. Instead, a picornavirus '2A-like' motif is inserted in-frame between the 10 HDAg and the IFN-3 coding sequence, creating rHDV-HDAg-2A-huIFNbeta (Figure 5). The insertion of a '2A-like' motif allows the expression of two or more proteins from a single open reading frame (de Felipe et al., 2006, Trends Biotechnol. 24(2):68 75) by a translational recoding event in which a peptide bond is 'skipped' during elongation (Doronina et al., 2008, supra). Since the function of the '2A-like' motif is 15 believed to be mediated by amino acids rather than the coding sequence, the G/C content of rHDV-HDAg-2A-huIFNbeta can be fully controlled, i.e., all artificially inserted sequences can be edited to match G/C levels found in the wild-type HDV backbone. Another advantage of using a '2A-like' sequence element is that these elements are relatively short. For example a particular '2A-like' sequence disclosed by 20 Osborne et al., (2005, Mol Ther 12: 569-574) comprises only 63 nts. As a consequence, rHDV-HDAg-2A-huIFNbeta is much smaller than the other two recombinant genomes, which may enhance efficient packaging of recombinant HDV genomes. EXAMPLE 5 RECOMBINANT HDV CONSTRUCT WHERE INSERTION IS DOWNSTREAM OF THE 25 RIBOZYME [0227] Another strategy for insertion and expression of heterologous nucleotide sequences in HDV is shown in Figure 7, which illustrates a schematic representation of the construct rHDV-HDAg-ribo-insertion. In this construct, an heterologous nucleotide sequence of interest, which comprises a coding sequence (e.g., 30 IFN-3 coding sequence) is inserted downstream of the ribozyme and upstream of the 'tip' of the rod. - 66 - [0228] The disclosure of every patent, patent application, and publication cited herein is hereby incorporated herein by reference in its entirety. [0229] The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application. 5 [0230] Throughout the specification the aim has been to describe the preferred embodiments of the invention without limiting the invention to any one embodiment or specific collection of features. Those of skill in the art will therefore appreciate that, in light of the instant disclosure, various modifications and changes can be made in the particular embodiments exemplified without departing from the scope of 10 the present invention. All such modifications and changes are intended to be included within the scope of the appended claims. - 67 -
Claims (60)
1. A recombinant single-stranded, circular hepatitis delta virus (HDV) RNA genome, which comprises in operable connection: a promoter; an open reading frame (ORF) for a hepatitis delta antigen (HDAg); a polyadenylation signal; and a HDV 5 ribozyme, wherein the genome comprises substantially complementary portions conferring a rod-like secondary structure, the genome characterized in that it comprises at a first site a first heterologous nucleotide sequence and at a second site a second heterologous nucleotide sequence that is substantially complementary to the first heterologous nucleotide sequence wherein the first and second sites are spaced from 10 each other to permit annealing between the first and second heterologous nucleotide sequences.
2. A recombinant single-stranded, circular hepatitis delta virus (HDV) RNA genome comprising a first portion and a second portion, wherein the first portion comprises in operable connection: (1) a promoter; (2) an open reading frame (ORF) for 15 a hepatitis delta antigen (HDAg); (3) a polyadenylation signal; (4) a HDV ribozyme; and (5) a first heterologous nucleotide sequence, and wherein the second portion is substantially complementary to the first portion so as to permit annealing between the portions.
3. A recombinant single-stranded, circular hepatitis delta virus (HDV) RNA 20 genome comprising a first portion and a second portion, wherein the first portion comprises in operable connection: (1) a promoter; (2) an open reading frame (ORF) for a hepatitis delta antigen (HDAg); (3) a polyadenylation signal; (4) a HDV ribozyme; and (5) a first heterologous nucleotide sequence, and wherein the second portion is substantially complementary to the first portion so as to permit annealing between the 25 portions and to confer a rod-like secondary structure to the genome.
4. A recombinant genome according to claim 2 or claim 3, wherein the second portion comprises a second heterologous nucleotide sequence that is substantially complementary to the first heterologous nucleotide sequence to permit annealing between the first and second heterologous nucleotide sequences. 30
5. A recombinant genome according to any one of claims 1 to 4, wherein the first heterologous nucleotide sequence is located downstream of the promoter and upstream of the ORF. - 68 -
6. A recombinant genome according to claim 5, wherein the first heterologous nucleotide sequence comprises a coding sequence for an exogenous polypeptide, which is operably connected to the promoter, and an internal ribosome entry site (IRES) that is operably connected to the ORF. 5
7. A recombinant genome according to any one of claims 1 to 4, wherein the first heterologous nucleotide sequence is located downstream of the ORF.
8. A recombinant genome according to claim 7, wherein the first heterologous nucleotide sequence is located upstream of the polyadenylation site.
9. A recombinant genome according to claim 8, wherein the first heterologous 10 nucleotide sequence comprises an internal ribosome entry site (IRES) operably connected to a coding sequence for an exogenous polypeptide.
10. A recombinant genome according to any one of claims 5, 7 or 8, wherein the first heterologous nucleotide sequence comprises a first coding sequence for an exogenous polypeptide and a second coding sequence for a proteolytic cleavage site, 15 wherein the first and second coding sequences are in frame with each other and with the ORF to thereby encode a precursor polypeptide, wherein the proteolytic cleavage site is positioned between the exogenous polypeptide and the HDAg in the precursor polypeptide to facilitate release of the exogenous polypeptide upon proteolytic cleavage of the proteolytic cleavage site. 20
11. A recombinant genome according to any one of claims 5, 7 or 8, wherein the first heterologous nucleotide sequence comprises a first coding sequence for an exogenous polypeptide and a second coding sequence for a self-cleaving, wherein the first and second coding sequences are in frame with each other and with the ORF.
12. A recombinant genome according to claim 10 or claim 11, wherein the first 25 heterologous nucleotide sequence is located downstream of the promoter and upstream of the ORF, and wherein the second coding sequence is downstream of the first coding sequence and upstream of the ORF.
13. A recombinant genome according to claim 10 or claim 11, wherein the first heterologous nucleotide sequence is located downstream of the ORF, and wherein the 30 second coding sequence is upstream of the first coding sequence and downstream of the ORF.
14. A recombinant genome according to any one of claims 1 to 4, wherein the first heterologous nucleotide sequence is located downstream of the HDV ribozyme. - 69 -
15. A recombinant genome according to claim 14, wherein the first heterologous nucleotide sequence is operably connected to another promoter.
16. A recombinant genome according to any one of claims 1 and 4 to 15, wherein the first heterologous nucleotide sequence has a G/C nucleotide content of 5 about 55-65%.
17. A recombinant genome according to any preceding claim, wherein the first heterologous nucleotide sequence has a G/C nucleotide content of about 60%.
18. A recombinant genome according to any preceding claim, wherein the first heterologous nucleotide sequence has at least about 50% (and at least 51% to at least 10 99% and all integer percentages in between) sequence identity to the second heterologous nucleotide sequence.
19. A recombinant genome according to any preceding claim, wherein the first heterologous nucleotide sequence comprises a coding sequence for an exogenous polypeptide, wherein the exogenous polypeptide is a cytokine. 15
20. A recombinant genome according to claim 19, wherein the cytokine attenuates the HDV.
21. A recombinant genome according to claim 19 or claim 20, wherein the cytokine is an interferon (IFN).
22. A recombinant genome according to any one of claims 19 to 21, wherein 20 the cytokine is a type I IFN.
23. A recombinant genome according to claim 23, wherein the cytokine is IFN P:.
24. A recombinant genome according to any one of claims 1 to 18, wherein the first heterologous nucleotide sequence comprises a coding sequence for an exogenous 25 polypeptide, and wherein the exogenous polypeptide is selected from a polypeptide of a pathogenic organism, an alloantigen, an autoantigen, a cancer or tumor antigen or any other polypeptide that has therapeutic activity.
25. A recombinant genome according to any preceding claim, wherein the first heterologous nucleotide sequence comprises a coding sequence for an exogenous 30 polypeptide, and wherein the coding sequence further comprises a nucleotide sequence encoding a signal peptide for transit of the exogenous polypeptide to a particular cellular compartment or into an extracellular environment. - 70 -
26. A recombinant genome according to claim 25, wherein the nucleotide sequence encoding the signal peptide is positioned upstream of the coding sequence for the exogenous polypeptide.
27. A recombinant genome according to claim 25, wherein the signal peptide 5 directs translocation of the exogenous polypeptide across an endoplasmic reticulum (ER) membrane within a host cell infected by the virus.
28. A recombinant genome according to any preceding claim, wherein the first heterologous nucleotide sequence comprises a coding sequence for an exogenous polypeptide, and wherein the exogenous polypeptide is exported to the host cell surface, 10 presented on the cell surface as a peptide with a major histocompatibility antigen, secreted from the cell, or remains in the cytoplasm of the cell.
29. A recombinant genome according to any one of claims 1 to 4, wherein the first heterologous nucleotide sequence comprises a nucleotide sequence that is only transcribed into RNA. 15
30. A nucleic acid molecule comprising a sequence corresponding to the recombinant genome of any preceding claim or to an antigenome thereof.
31. A vector comprising the nucleic acid molecule of claim 30.
32. A recombinant hepatitis delta virus (HDV) comprising the genome of any one of claims 1 to 29. 20
33. A pharmaceutical composition comprising a recombinant HDV according to claim 32, and a pharmaceutically acceptable excipient, diluent or carrier.
34. An immunomodulating composition comprising a recombinant HDV according to claim 32, and optionally an adjuvant or immunostimulant.
35. A method for eliciting an immune response to a hepatitis delta virus (HDV) 25 in a subject, the method comprising administering to the subject an effective amount of a recombinant HDV according to claim 32 so as to elicit an immune response to the HDV.
36. A method for treating or preventing a hepatitis delta virus (HDV) infection in a subject, the method comprising administering an effective amount of a recombinant 30 HDV according to claim 32 to the subject.
37. A recombinant hepatitis delta virus (HDV) according to claim 32, or a composition according to claim 33 or claim 34, for use in inducing an immune response to a HDV in a subject. -71 -
38. A method for eliciting an immune response to an exogenous polypeptide in a subject, the method comprising administering a recombinant hepatitis delta virus (HDV) according to claim 32 to the subject so as to elicit an immune response to the exogenous polypeptide. 5
39. A method according to claim 38, wherein the exogenous polypeptide is an antigen of the subject or an antigen of a microorganism.
40. A recombinant hepatitis delta virus (HDV) according to claim 32, or a composition according to claim 33 or claim 34, for use in preventing or treating an infection by a pathogen in a subject. 10
41. A method for delivering an exogenous polypeptide having therapeutic activity to a subject, the method comprising administering a hepatitis delta virus (HDV) according to claim 32 to the subject, whereby the exogenous polypeptide is produced in a host cell of the subject.
42. A method according to claim 41, wherein the host cell is a hepatocyte. 15
43. A method according to claim 41 or claim 42, wherein the therapeutic polypeptide remains inside the cell.
44. A method according to claim 41 or claim 42, wherein the therapeutic polypeptide becomes associated with a cell membrane.
45. A method according to claim 41 or claim 42, wherein the therapeutic 20 polypeptide is secreted from the cell.
46. A method for producing an exogenous polypeptide in a host cell (e.g., a vertebrate host cell), the method comprising contacting a susceptible host cell with a recombinant hepatitis delta virus (HDV) according to claim 32, wherein the first heterologous nucleotide sequence comprises a coding sequence for the exogenous 25 polypeptide, and culturing the host cell for a period of time to allow production of the exogenous polypeptide by the host cell.
47. A method according to claim 46, further comprising purifying the exogenous polypeptide.
48. A method for producing a recombinant single-stranded, circular hepatitis 30 delta virus (HDV) RNA genome, the method comprising: providing a parent single stranded, circular HDV RNA genome, which comprises in operable connection: a promoter; an open reading frame (ORF) for a hepatitis delta antigen (HDAg); a polyadenylation signal; and a HDV ribozyme, and which has substantially - 72 - complementary portions that anneal to one another and confer a rod-like secondary structure on the parent genome, and inserting into the parent genome at a first site a first heterologous nucleotide sequence and at a second site a second heterologous nucleotide sequence that is substantially complementary to the first heterologous nucleotide 5 sequence to form the recombinant HDV genome, wherein the first and second sites are spaced from each other in the recombinant genome to permit annealing between the first and second heterologous nucleotide sequences.
49. A method according to claim 48, comprising inserting the first and second heterologous nucleotide sequences such that they do not interfere or impair annealing of 10 the complementary portions of the parent genome.
50. A method according to claim 48 or claim 49, comprising inserting the first heterologous nucleotide sequence downstream of the promoter and upstream of the ORF and inserting the second heterologous nucleotide sequence downstream of the nucleotide sequence of the parent genome that is substantially complementary and 15 anneals to the ORF and upstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the promoter.
51. A method according to claim 48 or claim 49, comprising inserting the first heterologous nucleotide sequence downstream of the ORF and upstream of the polyadenylation signal and inserting the second heterologous nucleotide sequence 20 downstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the polyadenylation signal and upstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the ORF.
52. A method according to claim 48 or claim 49, comprising inserting the first 25 heterologous nucleotide sequence downstream of the ribozyme and upstream of portions of the parent genome that are substantially complementary and anneal to each other and inserting the second heterologous nucleotide sequence downstream of those portions and upstream of the nucleotide sequence of the parent genome that is substantially complementary and anneals to the ribozyme. 30
53. A method according to any one of claims 48 to 53, wherein the first heterologous nucleotide sequence has at least 70% sequence identity to the second heterologous nucleotide sequence. - 73 -
54. A method according to any one of claims 48 to 54, further comprising modifying the G/C content of the first and second heterologous nucleotide sequences to substantially accord with the G/C content of the parent genome.
55. A method according to claim 54, wherein the first and second heterologous 5 nucleotide sequences have a G/C nucleotide content of between about 55% to about 65%.
56. A method according to claim 54, wherein the first and second heterologous nucleotide sequences have a G/C nucleotide content of about 60%.
57. A method for treating or preventing a hepatitis infection in a subject, the 10 method comprising, consisting or consisting essentially of administering an effective amount of a recombinant HDV according to claim 32, wherein the first heterologous nucleotide sequence comprises a coding sequence for a cytokine.
58. A method according to claim 57, wherein the cytokine is an interferon.
59. A method according to claim 57, wherein the cytokine is an interferon is 15 selected from a type I IFN, a type II IFN or a type III IFN.
60. A method according to claim 59, wherein the a type I IFN is IFN-a or IFN - 74 -
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013203696A AU2013203696A1 (en) | 2012-06-25 | 2013-04-11 | Recombinant Viral Vectors and Uses Therefor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012902684 | 2012-06-25 | ||
AU2012902684A AU2012902684A0 (en) | 2012-06-25 | Recombinant Viral Vectors and Uses Therefor | |
AU2013203696A AU2013203696A1 (en) | 2012-06-25 | 2013-04-11 | Recombinant Viral Vectors and Uses Therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2013203696A1 true AU2013203696A1 (en) | 2014-01-16 |
Family
ID=49781940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013203696A Abandoned AU2013203696A1 (en) | 2012-06-25 | 2013-04-11 | Recombinant Viral Vectors and Uses Therefor |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2013203696A1 (en) |
WO (1) | WO2014000026A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3115891A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
CN117384961A (en) * | 2016-02-23 | 2024-01-12 | 萨克生物研究学院 | Treatment of exogenous gene expression in adenoviruses with minimal effect on viral kinetics |
EP3390428B1 (en) | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
CN110062630A (en) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | Cancer target synthesizes adenovirus and application thereof |
US20230203192A1 (en) * | 2020-05-20 | 2023-06-29 | Flagship Pioneering, Inc. | Compositions and methods for producing human polyclonal antibodies |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
-
2013
- 2013-04-11 AU AU2013203696A patent/AU2013203696A1/en not_active Abandoned
- 2013-06-25 WO PCT/AU2013/000681 patent/WO2014000026A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2014000026A1 (en) | 2014-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11478544B2 (en) | Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines contaning hepatitis B virus genes | |
US9987353B2 (en) | Virus like vesicles (VLVS) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection | |
AU2013203696A1 (en) | Recombinant Viral Vectors and Uses Therefor | |
US20230406889A1 (en) | Live-attenuated flaviviruses with heterologous antigens | |
WO2022071513A1 (en) | IMPROVED DNA VACCINE FOR SARS-CoV-2 | |
US11160857B2 (en) | Multivalent enterovirus vaccine compositions and uses related thereto | |
WO2013188918A1 (en) | Improved recombinant viruses | |
JP2022524007A (en) | Hepatitis B immunization regimen and composition | |
Neeli et al. | Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2 | |
US20220402976A1 (en) | Chimeric filovirus vaccines | |
CN113164582A (en) | Chimeric flavivirus Lisa virus vaccine | |
OA20740A (en) | Lassavirus vaccines. | |
WO2021048402A1 (en) | Lassavirus vaccines | |
TWI302166B (en) | ||
Guo et al. | A Bicistronic DNA Vaccine Containing Gene of FMDV and Bovine IFN-\alpha Can Prime Humoral and Cellular Immune Responses of Guinea Pigs | |
CN114341361A (en) | Methods and compositions of astrovirus replicons | |
WO2019068885A1 (en) | Chimeric yellow fever zika virus strain | |
WO2004082712A1 (en) | Bivalent vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |